<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>Current Neurology and Neuroscience Reports via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Current Neurology and Neuroscience Reports' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Current+Neurology+and+Neuroscience+Reports&t=Current+Neurology+and+Neuroscience+Reports&s=Search&f=source]]></link>
        <lastBuildDate>Tue, 07 Feb 2012 07:05:42 +0100</lastBuildDate>
        <item>
            <title>OnabotulinumtoxinA in Pediatric Chronic Daily Headache</title>
            <link>http://www.medworm.com/index.php?rid=5636690&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F757m081l7mqp0321%2F</link>
            <description>This study showed a major change in the frequency of the
 headache with a statistical difference in the improvement of headache days per month. There was a 30-point drop in the pediatric
 disability scoring between first injection and follow-up injection with a change from severe disability to moderate disability.
 
 
	Content Type Journal ArticleCategory Headache (I Garza, Section Editor)Pages 1-4DOI 10.1007/s11910-012-0251-1Authors
		Marielle Kabbouche, Division of Neurology, Cincinnati Children’s Hospital Medical Center, Headache Center, MLC #2015, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USAHope O’Brien, Division of Neurology, Cincinnati Children’s Hospital Medical Center, Headache Center, MLC #2015, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USAAndrew D. Hershey, Divis...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5636690</comments>
            <pubDate>Tue, 24 Jan 2012 12:27:04 +0100</pubDate>
            <guid isPermaLink="false">5636690</guid>        </item>
        <item>
            <title>Temozolomide for Pediatric High-Grade Gliomas</title>
            <link>http://www.medworm.com/index.php?rid=5618162&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy727gj33842286q6%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trial ReportPages 1-3DOI 10.1007/s11910-012-0250-2Authors
		Roger J. Packer, Center for Neuroscience and Behavioral Medicine, Children’s National Medical Center, Gilbert Neurofibromatosis Institute, Brain Tumor Institute, 111 Michigan Avenue, NW, Washington, DC 20010, USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5618162</comments>
            <pubDate>Tue, 17 Jan 2012 07:06:32 +0100</pubDate>
            <guid isPermaLink="false">5618162</guid>        </item>
        <item>
            <title>Sleep-Disordered Breathing in Neurodegenerative Diseases</title>
            <link>http://www.medworm.com/index.php?rid=5618161&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F017qk7892kn71525%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Sleep disorders are common in neurodegenerative diseases such as Parkinson’s disease (PD), multiple system atrophy (MSA),
 amyotrophic lateral sclerosis (ALS), hereditary ataxias, and Alzheimer’s disease (AD). Type, frequency, and severity of sleep
 disturbances vary depending on each of these diseases. Cell loss of the brainstem nuclei that modulates respiration, and dysfunction
 of bulbar and diaphragmatic muscles increase the risk for sleep-disordered breathing (SDB) in MSA and ALS. The most relevant
 SDB in MSA is stridor, whereas in ALS nocturnal hypoventilation due to diaphragmatic weakness is the most common sleep breathing
 abnormality. Stridor and nocturnal hypoventilation are associated with reduced survival in MSA and ALS. In contrast, sleep
 apnea seems ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5618161</comments>
            <pubDate>Tue, 17 Jan 2012 07:06:32 +0100</pubDate>
            <guid isPermaLink="false">5618161</guid>        </item>
        <item>
            <title>Narcolepsy in the Pediatric Population</title>
            <link>http://www.medworm.com/index.php?rid=5570402&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe305525323280578%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Narcolepsy is characterized by excessive daytime sleepiness, with or without cataplexy. Associated features include sleep
 paralysis, hypnagogic or hypnopompic hallucinations, and disturbed nocturnal sleep. Narcolepsy is strongly associated with
 the HLA DQB1*0602 allele, and its symptoms stem from destruction of hypocretin-secreting neurons in the hypothalamus. Recently
 identified autoantibodies to Tribbles homologue 2 in some patients, as well as cases associated with H1N1 vaccination, support
 an autoimmune mechanism. There are many challenges in diagnosing and treating pediatric narcolepsy. Caution must also be used
 in interpreting polysomnography and multiple sleep latency test results in children. HLA testing is nonspecific, and no commercial
 test exists to mea...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5570402</comments>
            <pubDate>Tue, 03 Jan 2012 06:44:58 +0100</pubDate>
            <guid isPermaLink="false">5570402</guid>        </item>
        <item>
            <title>Syndromes Predisposing to Pediatric Central Nervous System Tumors: Lessons Learned and New Promises</title>
            <link>http://www.medworm.com/index.php?rid=5557385&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft3mhgg6253m48706%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Central nervous system (CNS) neoplasms are a leading cause of morbidity and mortality among children with cancer. In contrast
 to adults, a genetic basis for brain tumors is relatively common in children. A child harboring a germline mutation in a cancer-related
 gene will be predisposed to develop CNS tumors. These cancer predisposition syndromes are rare but pose overwhelming clinical
 and psychosocial challenges to families and the treating team. Recent significant advances in our understanding of the biological
 processes that govern these genetic conditions combined with international efforts to define and treat clinical aspects of
 these tumors are transforming the lives of these individuals. In this article, we summarize recent progress made for each
 of the majo...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5557385</comments>
            <pubDate>Wed, 28 Dec 2011 16:50:06 +0100</pubDate>
            <guid isPermaLink="false">5557385</guid>        </item>
        <item>
            <title>Recent Advances in Diagnostic Strategies for Giant Cell Arteritis</title>
            <link>http://www.medworm.com/index.php?rid=5557386&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fhk11q56771534753%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Giant cell arteritis (GCA) is a systemic vasculitis that affects the aorta and its major branches. Involvement of the ciliary
 artery can result in ischemic optic neuropathy and subsequent blindness, which is typically irreversible. If GCA is suspected,
 treatment with glucocorticoids should be initiated promptly to prevent further vision loss. However, given the need for prolonged
 therapy with glucocorticoids and the morbidity associated with their use, diagnosis should be confirmed. Clinical features
 and laboratory findings are neither sensitive nor specific for GCA. The mainstay of diagnosis remains histopathologic examination
 of a section of the superficial temporal artery. Several imaging studies have been used to evaluate the temporal artery but,
 at present, t...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5557386</comments>
            <pubDate>Wed, 28 Dec 2011 16:50:04 +0100</pubDate>
            <guid isPermaLink="false">5557386</guid>        </item>
        <item>
            <title>Nummular Headache Update</title>
            <link>http://www.medworm.com/index.php?rid=5557387&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8434525760613066%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Nummular headache is characterized by head pain exclusively felt in a rounded or elliptical area, typically 1 to 6&amp;nbsp;cm in diameter.
 The pain remains confined to the same symptomatic area, which does not change in shape or size with time. The symptomatic
 area may be localized in any part of the head but mostly in the parietal region. Rarely, the disorder may be multifocal, each
 symptomatic area keeping all the characteristics of nummular headache. The pain is generally mild or moderate, commonly described
 as oppressive or stabbing, and lasting minutes, hours, or days, with a remitting or unremitting pattern. Superimposed on the
 baseline pain, there may be spontaneous or triggered exacerbations. During and between symptomatic periods, the affected area
 may show ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5557387</comments>
            <pubDate>Tue, 27 Dec 2011 16:51:41 +0100</pubDate>
            <guid isPermaLink="false">5557387</guid>        </item>
        <item>
            <title>Nocebo in Headaches: Implications for Clinical Practice and Trial Design</title>
            <link>http://www.medworm.com/index.php?rid=5542898&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F815900112q1576w6%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The term nocebo refers to a harmful, unpleasant or undesirable adverse event a subject manifests after receiving an inert
 dummy drug or placebo. This reaction is originating by the patients fear and negative expectation that medical treatment most
 likely will produce unfavorable consequences instead of healing. Like placebo, nocebo shares key functions in pain conditions.
 Two recent systemic meta-analyses searched for nocebo in trials for prevention of migraine and tension-type headache and revealed
 that 1 out of 20 patients treated with placebo withdraw treatment due to adverse effects. Additionally, adverse events in
 placebo groups mirrored the adverse events expected of the active medication studied, confirming that pretrial suggestions
 induce the adverse event...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5542898</comments>
            <pubDate>Thu, 22 Dec 2011 12:50:47 +0100</pubDate>
            <guid isPermaLink="false">5542898</guid>        </item>
        <item>
            <title>Surgical Management of Medically Refractory Trigeminal Neuralgia</title>
            <link>http://www.medworm.com/index.php?rid=5535257&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn277601101x75ng3%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The role of surgery for patients with medically refractory trigeminal neuralgia (TN) is well established. High-quality magnetic
 resonance imaging, including gadolinium-enhanced and volume acquisition sequences, should be performed to exclude intracranial
 tumors or demyelinating disease as the cause of the pain, as well as to clearly demonstrate the trigeminal nerve and adjacent
 blood vessels. For physiologically healthy patients with Type 1 TN, a microvascular decompression (MVD) is the preferred surgical
 approach because of its high rate of complete pain relief, the durability of the pain relief, and the fact that trigeminal
 injury is not required for pain relief. Patients with recurrent TN after a failed MVD, patients with significant medical comorbidities,
 and ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5535257</comments>
            <pubDate>Tue, 20 Dec 2011 06:43:23 +0100</pubDate>
            <guid isPermaLink="false">5535257</guid>        </item>
        <item>
            <title>Advances in the Laboratory Evaluation of Peripheral Neuropathies</title>
            <link>http://www.medworm.com/index.php?rid=5493247&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F872346k284972058%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Peripheral neuropathy is a common clinical problem in neurology and laboratory testing is an integral part of diagnosis. In
 the past few years, practice parameters have been published to establish an evidence-based guide to neuropathy testing. There
 are many tests that are common and accepted in practice, but there is no clear mandate on which tests are necessary. This
 article reviews recent practice parameter publications as well as other updates in laboratory testing for peripheral neuropathy,
 including the roles of lipid profile, genetic testing, antibody titers, and B12 testing in a specific dopamine-treated Parkinson’s patients. These can serve as recommendations to help guide laboratory
 testing.
 
 
	Content Type Journal ArticleCategory Nerve and Muscle (M ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5493247</comments>
            <pubDate>Tue, 06 Dec 2011 17:03:11 +0100</pubDate>
            <guid isPermaLink="false">5493247</guid>        </item>
        <item>
            <title>New Therapeutic Approaches to Spinal Muscular Atrophy</title>
            <link>http://www.medworm.com/index.php?rid=5474510&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv787545v608724h4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Bench to bedside progress has been widely anticipated for a growing number of neurodegenerative disorders. Of these, spinal
 muscular atrophy (SMA) is perhaps the best poised to capitalize on advances in targeted therapeutics development over the
 next few years. Several laboratories have achieved compelling success in SMA animal models using sophisticated methods for
 targeted delivery, repair, or increased expression of the survival motor neuron protein, SMN. The clinical community is actively
 collaborating to identify, develop, and validate outcome measures and biomarkers in parallel with laboratory efforts. Innovative
 trial design and synergistic approaches to maximize proactive care in conjunction with treatment with one or more of the promising
 pharmacologic an...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5474510</comments>
            <pubDate>Thu, 01 Dec 2011 19:29:50 +0100</pubDate>
            <guid isPermaLink="false">5474510</guid>        </item>
        <item>
            <title>Tools and Early Management of Language and Swallowing Disorders in Acute Stroke Patients</title>
            <link>http://www.medworm.com/index.php?rid=5455207&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F54117036m6157823%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The role of the stroke units in improving morbidity, mortality, and recovery from stroke is clearly demonstrated. However,
 acute management of language disorders in these specialized units remains controversial, and management of swallowing disorders
 is usually nonstandardized. The recent validation of a scale for rapid screening of language disorders (LAST [Language Screening
 Test]) in acute stroke patients should allow optimization of their detection and early management. Swallowing disorders should
 be screened and managed using a standardized protocol. Following early initial evaluation repeated on a daily basis, they
 justify tailored rehabilitation sessions, adaptation of food textures, team formation, and families’ information. The use
 of these protocols im...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5455207</comments>
            <pubDate>Fri, 25 Nov 2011 06:44:33 +0100</pubDate>
            <guid isPermaLink="false">5455207</guid>        </item>
        <item>
            <title>An Update on Monoclonal Gammopathy and Neuropathy</title>
            <link>http://www.medworm.com/index.php?rid=5429250&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd24j577762680852%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Peripheral neuropathy associated with monoclonal gammopathy is a rare but important cause of neuropathy that can herald serious
 underlying disease. IgM monoclonal gammopathy of undetermined significance (MGUS) is the most commonly found monoclonal gammopathy
 associated with neuropathy, with characteristic clinical, electrophysiologic, and pathologic features. The IgG and IgA monoclonal
 gammopathies are rarely associated with specific neuropathies. Standard immunomodulatory agents including steroids, intravenous
 immunoglobulin, and plasmapheresis have shown limited efficacy in IgM MGUS. Neuropathies associated with specific lymphoproliferative
 disorders may not respond to treatments aimed at that disorder. Case series had shown promising results with rituximab, a
 m...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5429250</comments>
            <pubDate>Thu, 17 Nov 2011 06:57:44 +0100</pubDate>
            <guid isPermaLink="false">5429250</guid>        </item>
        <item>
            <title>Novel Insights into the Pathomechanisms of Skeletal Muscle Channelopathies</title>
            <link>http://www.medworm.com/index.php?rid=5419637&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc12t07842558774x%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The nondystrophic myotonias and primary periodic paralyses are an important group of genetic muscle diseases characterized
 by dysfunction of ion channels that regulate membrane excitability. Clinical manifestations vary and include myotonia, hyperkalemic
 and hypokalemic periodic paralysis, progressive myopathy, and cardiac arrhythmias. The severity of myotonia ranges from severe
 neonatal presentation causing respiratory compromise through to mild later-onset disease. It remains unclear why the frequency
 of attacks of paralysis varies greatly or why many patients develop a severe permanent fixed myopathy. Recent detailed characterizations
 of human genetic mutations in voltage-gated muscle sodium (gene: SCN4A), chloride (gene: CLCN1), calcium (gene: CACNA1S), and inw...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5419637</comments>
            <pubDate>Mon, 14 Nov 2011 16:52:51 +0100</pubDate>
            <guid isPermaLink="false">5419637</guid>        </item>
        <item>
            <title>Enzyme Replacement Therapy for Pompe Disease</title>
            <link>http://www.medworm.com/index.php?rid=5322308&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fax3x572148u816r0%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Late-onset glycogenosis type II (glycogen storage disease type II [GSDII]) is a rare autosomal disorder caused by deficiency
 of acid maltase, a lysosomal enzyme that hydrolyzes glycogen to glucose. Recently, both infantile and adult GSDII patients
 have been treated with enzyme replacement therapy (ERT), and a number of studies including large cohorts of GSDII patients
 have recently demonstrated that ERT is effective in modifying the natural course of the disease. The opportunity of this new
 treatment gave new hope to patients, but also an important impulse to the research on every feature of the disease, leading
 to a deeper knowledge on the response to treatment, on clinical manifestations, and on pathophysiologic aspects such as the
 role of autophagy and immune s...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5322308</comments>
            <pubDate>Fri, 14 Oct 2011 15:44:30 +0100</pubDate>
            <guid isPermaLink="false">5322308</guid>        </item>
        <item>
            <title>External Ventricular Drainage for Intraventricular Hemorrhage</title>
            <link>http://www.medworm.com/index.php?rid=5322309&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F95g506637p269468%2F</link>
            <description>We present a systematic review of the literature
 on the topic of EVD in the setting of IVH hemorrhage, articulating the scope of the problem and prognostic factors, clinical
 indications, surgical adjuncts, and other management issues.
 
 
	Content Type Journal ArticleCategory Stroke (HP Adams Jr, Section Editor)Pages 1-10DOI 10.1007/s11910-011-0231-xAuthors
		Mahua Dey, Hemorrhagic Stroke Research Unit, Section of Neurosurgery and the Neurovascular Surgery Program, Division of Biological Sciences and the Pritzker School of Medicine, The University of Chicago, 5841 South Maryland Ave, MC 3026, Room J341, Chicago, IL 60637, USAJennifer Jaffe, Hemorrhagic Stroke Research Unit, Section of Neurosurgery and the Neurovascular Surgery Program, Division of Biological Sciences and the Pritzker Sch...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5322309</comments>
            <pubDate>Fri, 14 Oct 2011 10:39:37 +0100</pubDate>
            <guid isPermaLink="false">5322309</guid>        </item>
        <item>
            <title>Congenital Myasthenic Syndromes in 2012</title>
            <link>http://www.medworm.com/index.php?rid=5322311&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fft3j212116430q82%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Congenital myasthenic syndromes (CMS) represent a heterogeneous group of disorders in which the safety margin of neuromuscular
 transmission is compromised by one or more specific mechanisms. Clinical, electrophysiologic, and morphologic studies have
 paved the way for detecting CMS-related mutations in proteins residing in the nerve terminal, the synaptic basal lamina, or
 in the postsynaptic region of the motor endplate. The disease proteins identified to date include the acetylcholine receptor,
 acetylcholinesterase, choline acetyltransferase, rapsyn, and Nav1.4, muscle-specific kinase, agrin, β2-laminin, downstream of tyrosine kinase 7, and glutamine-fructose-6-phosphate transaminase
 1. Analysis of electrophysiologic and biochemical properties of mutant proteins e...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5322311</comments>
            <pubDate>Thu, 13 Oct 2011 15:48:44 +0100</pubDate>
            <guid isPermaLink="false">5322311</guid>        </item>
        <item>
            <title>Use of Telemedicine and Other Strategies to Increase the Number of Patients That May Be Treated with Intravenous Thrombolysis</title>
            <link>http://www.medworm.com/index.php?rid=5322310&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp5061g2616583v1r%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Stroke is the fourth leading killer in the United States and a leading cause of adult long-term disability. The American Heart
 Association estimates that only 3% to 5% of patients with acute ischemic stroke are treated with intravenous thrombolysis.
 A way to improve the rates of treatment with thrombolysis in patients with acute ischemic stroke is the creation of telemedicine
 stroke networks. Data from many studies support the safety of expanding intravenous tissue plasminogen activator use with
 the help of telemedicine. In this article we discuss the current evidence for the use of telemedicine within stroke systems
 of care, the importance of coordinating care within the transferring facilities in the telestroke networks, telestroke economics
 and applicability, a...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5322310</comments>
            <pubDate>Thu, 13 Oct 2011 15:48:44 +0100</pubDate>
            <guid isPermaLink="false">5322310</guid>        </item>
        <item>
            <title>Intensive Care Unit Management of Aneurysmal Subarachnoid Hemorrhage</title>
            <link>http://www.medworm.com/index.php?rid=5322312&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq8v7475552v27504%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The emergence of dedicated neurologic-neurosurgical intensive care units, advancements in endovascular therapies, and aggressive
 brain resuscitation and monitoring have contributed to overall improved outcomes for patients with aneurysmal subarachnoid
 hemorrhage (aSAH) over the past 20 to 30&amp;nbsp;years. Still, this feared neurologic emergency is associated with substantial mortality
 and morbidity. Emergency care for patients with aSAH focuses on stabilization, treatment of the aneurysm, controlling intracranial
 hypertension to optimize cerebral perfusion, and limiting secondary brain injury. This complex disorder can be associated
 with many neurologic complications such as acute hydrocephalus, rebleeding, global cerebral edema, seizures, vasospasm, and
 delayed cer...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5322312</comments>
            <pubDate>Tue, 11 Oct 2011 05:49:30 +0100</pubDate>
            <guid isPermaLink="false">5322312</guid>        </item>
        <item>
            <title>Pain Disorders and Erythromelalgia Caused by Voltage-Gated Sodium Channel Mutations</title>
            <link>http://www.medworm.com/index.php?rid=5302463&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F15121008k5176231%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Voltage-gated sodium channels play a pivotal role in pain transmission. They are widely expressed in nociceptive neurons,
 and participate in the generation of action potentials. Alteration in ionic conduction of these channels causes abnormal electrical
 firing, thus renders neurons hyperexcitable. So far, mutations in the Nav1.7 sodium channel, which is expressed in the dorsal root ganglia cells and sympathetic neurons, have been described to cause
 perturbations in pain sensation. Until recently, gain-of-function Nav1.7 mutations were known to cause two neuropathic pain syndromes: inherited erythromelalgia and paroxysmal extreme pain syndrome.
 These syndromes are inherited in a dominant trait; they usually begin in childhood or infancy, and are characterized by atta...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5302463</comments>
            <pubDate>Fri, 07 Oct 2011 16:00:08 +0100</pubDate>
            <guid isPermaLink="false">5302463</guid>        </item>
        <item>
            <title>Update on Toxic Myopathies</title>
            <link>http://www.medworm.com/index.php?rid=5294711&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd1t227788j7wq278%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The toxic myopathies are a clinically and pathologically diverse group of disorders that can be caused by a variety of therapeutic
 agents used in clinical practice, as well as various venoms and other biological toxins. The most important iatrogenic causes
 are the statin and fibrate cholesterol-lowering agents that can cause a severe necrotizing myopathy and acute rhabdomyolysis
 and myoglobinuria. The current update focuses on the mechanisms of statin myotoxicity and the importance of genetic predisposing
 factors for statin myopathy, as well as the recently described form of necrotizing autoimmune myopathy, which is associated
 with antibodies to the 3-hydroxy-3-methylglutaryl-coenzyme A reductase enzyme and is responsive to aggressive immunotherapy.
 Mitochondrial ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5294711</comments>
            <pubDate>Tue, 04 Oct 2011 05:51:16 +0100</pubDate>
            <guid isPermaLink="false">5294711</guid>        </item>
        <item>
            <title>Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran</title>
            <link>http://www.medworm.com/index.php?rid=5282805&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd8487027106r5767%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Dabigatran is a direct inhibitor of thrombin that has recently been approved for primary and secondary stroke prevention and
 prevention of systemic embolism in patients with atrial fibrillation. The RE-LY (Randomized Evaluation of Long Term Anticoagulant
 Therapy [with Dabigatran Etexilate]) study showed that dabigatran given at a dose of 110&amp;nbsp;mg twice a day (bid) was associated
 with rates of stroke and systemic embolism that were similar to those associated with warfarin (International Normalized Ratio
 target 2.0–3.0), and lower rates of major hemorrhage. Dabigatran administered at a dose of 150&amp;nbsp;mg bid was significantly more
 effective compared with warfarin and showed a similar rate of major hemorrhages. Both dosages resulted in an approximately
 60% to ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5282805</comments>
            <pubDate>Fri, 30 Sep 2011 05:52:00 +0100</pubDate>
            <guid isPermaLink="false">5282805</guid>        </item>
        <item>
            <title>Intensity of Aphasia Therapy: Evidence and Efficacy</title>
            <link>http://www.medworm.com/index.php?rid=5282806&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F561571uj7231174j%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Determining the optimal amount and intensity of treatment is essential to the design and implementation of any treatment program
 for aphasia. A growing body of evidence, both behavioral and biological, suggests that intensive therapy positively impacts
 outcomes. We update a systematic review of treatment studies that directly compares conditions of higher and lower intensity
 treatment for aphasia. We identify five studies published since 2006, review them for methodologic quality, and synthesize
 their findings with previous ones. For both acute and chronic aphasia, results at the language impairment and communication
 activity/participation levels tend to be more equivocal than previously demonstrated, with no clear differences between intensive
 and nonintensive tr...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5282806</comments>
            <pubDate>Fri, 30 Sep 2011 05:51:59 +0100</pubDate>
            <guid isPermaLink="false">5282806</guid>        </item>
        <item>
            <title>Rhombencephalitis / Brainstem Encephalitis</title>
            <link>http://www.medworm.com/index.php?rid=5282807&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F677h7m3017p670x5%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Rhombencephalitis (RE) is a syndrome of multiple causes and multiple outcomes. Most authors now use the terms “rhombencephalitis”
 and “brainstem encephalitis” interchangeably even though anatomically they are slightly different. The etiologic categories
 of RE include infections, autoimmune diseases, and paraneoplastic syndromes (PNS). Listeria is the most common cause of infectious RE. Listeria RE primary occurs in healthy young adults. It usually occurs as a biphasic time course with a flu-like syndrome followed
 by brainstem dysfunction; 75% of patients have a cerebrospinal fluid (CSF) pleocytosis, and almost 100% have an abnormal brain
 MRI scan. Positive CSF and blood cultures are the most specific for diagnosis. Treatment primarily is with ampicillin. Ent...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5282807</comments>
            <pubDate>Thu, 29 Sep 2011 06:17:39 +0100</pubDate>
            <guid isPermaLink="false">5282807</guid>        </item>
        <item>
            <title>A West Nile Virus Vaccine</title>
            <link>http://www.medworm.com/index.php?rid=5258241&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg6033r5177270452%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trial ReportPages 1-3DOI 10.1007/s11910-011-0223-xAuthors
		Umair Afzal, Departments of Neurology, Microbiology/Immunology, and Neuroscience, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USABurk Jubelt, Departments of Neurology, Microbiology/Immunology, and Neuroscience, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5258241</comments>
            <pubDate>Thu, 22 Sep 2011 05:52:50 +0100</pubDate>
            <guid isPermaLink="false">5258241</guid>        </item>
        <item>
            <title>Clinical Manifestations, Diagnosis, and Treatment of Neurocysticercosis</title>
            <link>http://www.medworm.com/index.php?rid=5235368&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu69n68l424qgvh25%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Neurocysticercosis (NCC) is the most frequent parasitic disease of the human brain. Modern imaging studies, CT and MRI, have
 defined the diagnosis and characterization of the disease. Through these studies the therapeutic approach for each case may
 be individualized with the aid of antihelmintics, steroids, symptomatic medicines, or surgery. The use of one or various therapeutic
 measures largely depends on the peculiar combination of number, location, and biological stage of lesions as well as the degree
 of inflammatory response to the parasites. Although there is not a typical clinical picture of NCC, epilepsy is the most frequent
 manifestation of parenchymal NCC, whereas hydrocephalus is the most frequent manifestation of meningeal NCC. Eradication of
 cysticerco...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5235368</comments>
            <pubDate>Wed, 14 Sep 2011 05:45:08 +0100</pubDate>
            <guid isPermaLink="false">5235368</guid>        </item>
        <item>
            <title>Efficacy and Safety of Antidepressant Drugs in Patients with Dementia</title>
            <link>http://www.medworm.com/index.php?rid=5220558&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F63706817k2l0415g%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trial ReportPages 1-3DOI 10.1007/s11910-011-0222-yAuthors
		Howard S. Kirshner, Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5220558</comments>
            <pubDate>Fri, 09 Sep 2011 16:45:12 +0100</pubDate>
            <guid isPermaLink="false">5220558</guid>        </item>
        <item>
            <title>Borderzone Strokes and Transcortical Aphasia</title>
            <link>http://www.medworm.com/index.php?rid=5220559&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1817737130651826%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Borderzone infarcts (BZIs) are anatomically defined as ischemic lesions occurring at the junction between two arterial territories,
 accounting for 2% to 10% of strokes. Three types of hemispheric BZIs are described according to topography (ie, superficial
 anterior, posterior, and deep). Although published series on related aphasia are rare in the setting of BZI, aphasia is of
 transcortical (TCA) type, characterized by the preservation of repetition. TCA can be of motor, sensory, or mixed type depending
 on whether expression, understanding, or both are impaired. Recent studies have reported specific aphasic patterns. BZI patients
 initially presented with mixed TCA. Aphasia specifically evolved according to the stroke location, toward motor or sensory
 TCA in patient...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5220559</comments>
            <pubDate>Fri, 09 Sep 2011 05:46:23 +0100</pubDate>
            <guid isPermaLink="false">5220559</guid>        </item>
        <item>
            <title>Neurologic Manifestations of Chagas Disease</title>
            <link>http://www.medworm.com/index.php?rid=5220560&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F828176uv10611p58%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Chagas disease is endemic in Latin America and has become an emerging problem in developed countries because of international
 migrations. The protozoan Trypanosoma cruzi is the etiologic agent and the disease is divided into two phases. The acute phase is mostly asymptomatic or presents with
 unspecific symptoms. Rarely, a severe and often fatal form occurs in immunosuppressed patients or infants, characterized by
 meningoencephalitis (sometimes including brain tumor–like lesions) and myocarditis. The chronic phase consists of an indeterminate,
 asymptomatic form followed by digestive, cardiac, or neurologic symptoms in about 30% of infected patients. Autonomous nervous
 system dysfunction is prominent in chagasic patients and participates in the affliction of the ta...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5220560</comments>
            <pubDate>Fri, 09 Sep 2011 05:46:21 +0100</pubDate>
            <guid isPermaLink="false">5220560</guid>        </item>
        <item>
            <title>Transient Global Amnesia: A Brief Review and Update</title>
            <link>http://www.medworm.com/index.php?rid=5205499&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy1232756104617pv%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Transient global amnesia (TGA) is a transitory syndrome of memory loss, lasting less than 24&amp;nbsp;h. Although there are many known
 causes of transient amnesia, the syndrome of TGA remains of unknown etiology. Known causes of transient amnesia, theories
 of pathogenesis of TGA, and recommended evaluation and treatment are discussed.
 
 
	Content Type Journal ArticleCategory Behavior (Howard S. Kirshner, Section Editor)Pages 1-5DOI 10.1007/s11910-011-0224-9Authors
		Howard S. Kirshner, Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5205499</comments>
            <pubDate>Tue, 06 Sep 2011 05:48:48 +0100</pubDate>
            <guid isPermaLink="false">5205499</guid>        </item>
        <item>
            <title>Brain MRI in Neuromyelitis Optica: What is its Role?</title>
            <link>http://www.medworm.com/index.php?rid=5174444&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv44p681q271p2r52%2F</link>
            <description>Content Type Journal ArticleCategory Invited CommentaryPages 1-3DOI 10.1007/s11910-011-0220-0Authors
		Wei Qiu, Multiple Sclerosis Center, Department of Neurology, the Third Affiliated Hospital of Sun yat-sen University, No.600 Tianhe Road, Tianhe District, Guangzhou, China 510630Allan G. Kermode, Centre for Neuromuscular and Neurological disorders, University of Western Australia, Perth, Western Australia, Australia
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5174444</comments>
            <pubDate>Thu, 25 Aug 2011 15:49:28 +0100</pubDate>
            <guid isPermaLink="false">5174444</guid>        </item>
        <item>
            <title>Cognitive Impairment in Huntington Disease: Diagnosis and Treatment</title>
            <link>http://www.medworm.com/index.php?rid=5158132&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa064w6m10g669622%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cognition has been well characterized in the various stages of Huntington disease (HD) as well as in the prodrome before the
 motor diagnosis is given. Although the clinical diagnosis of HD relies on the manifestation of motor abnormalities, the associated
 impairments have been growing in prominence for several reasons. First, research to understand the most debilitating aspects
 of HD has suggested that cognitive and behavioral changes place the greatest burden on families, are most highly associated
 with functional decline, and can be predictive of institutionalization. Second, cognitive impairments are evident at least
 15&amp;nbsp;years prior to the time at which motor diagnosis is given. Finally, cognitive decline is associated with biological markers
 such as brain ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5158132</comments>
            <pubDate>Mon, 22 Aug 2011 15:59:14 +0100</pubDate>
            <guid isPermaLink="false">5158132</guid>        </item>
        <item>
            <title>Naming and the Role of the Uncinate Fasciculus in Language Function</title>
            <link>http://www.medworm.com/index.php?rid=5158133&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv37ux484441333j3%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In this paper, an overview of the studies relating naming to the uncinate fasciculus is reported. With the introduction of
 contemporary neuroimaging techniques, namely of diffusion tensor imaging, white matter tracts have been investigated more
 thoroughly and possible changes in the uncinate fasciculus integrity have been correlated to different neuropsychological
 deficits. Although previous research has proposed a role of the left uncinate fasciculus on action and object naming or in
 semantic processing, a more recent study has suggested that naming famous people could be the most relevant task in which
 this bundle is involved, the semantic component being intact. The uncinate fasciculus connects the orbitofrontal cortex, involved
 in face encoding and in processi...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5158133</comments>
            <pubDate>Fri, 19 Aug 2011 05:51:13 +0100</pubDate>
            <guid isPermaLink="false">5158133</guid>        </item>
        <item>
            <title>Personalized Treatment in Multiple Sclerosis</title>
            <link>http://www.medworm.com/index.php?rid=5130485&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F188u7r7152212868%2F</link>
            <description>Content Type Journal ArticlePages 1-3DOI 10.1007/s11910-011-0218-7Authors
		Jorge Correale, Department of Neurology, Raúl Carrea Institute for Neurological Research, FLENI, Montañeses 2325, 1428 Buenos Aires, Argentina
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5130485</comments>
            <pubDate>Sat, 13 Aug 2011 06:05:25 +0100</pubDate>
            <guid isPermaLink="false">5130485</guid>        </item>
        <item>
            <title>Cognitive Impairment and MS: Searching for Effective Therapies</title>
            <link>http://www.medworm.com/index.php?rid=5085773&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy5227864351mv175%2F</link>
            <description>Content Type Journal ArticlePages 1-4DOI 10.1007/s11910-011-0217-8Authors
		Vijayshree Yadav, Department of Neurology, Oregon Health &amp; Science University, 3181 SW Sam Jackson Park Road, UHS-42, Portland, OR 97239, USADennis N. Bourdette, Department of Neurology, Oregon Health &amp; Science University, 3181 SW Sam Jackson Park Road, UHS-42, Portland, OR 97239, USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5085773</comments>
            <pubDate>Fri, 29 Jul 2011 16:04:13 +0100</pubDate>
            <guid isPermaLink="false">5085773</guid>        </item>
        <item>
            <title>Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions</title>
            <link>http://www.medworm.com/index.php?rid=5069161&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy320252v533v1841%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The oral sphingosine 1-phosphate receptor (S1PR) modulator fingolimod functionally antagonizes S1PR hereby blocking lymphocyte
 egress from secondary lymphoid organs to the peripheral blood circulation. This results in a reduction in peripheral lymphocyte
 counts, including potentially encephalitogenic T cells. In patients with relapsing multiple sclerosis fingolimod has been
 shown to be an effective treatment. In phase 2 and phase 3 studies fingolimod-treated patients had reduced disease activity
 clinically and in MRI. Although severe infectious complications occurred in single cases treated with fingolimod, the frequency
 of overall infections was comparable in fingolimod-treated patients and controls. Overall, in clinical studies fingolimod
 was well tolerated and ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5069161</comments>
            <pubDate>Mon, 25 Jul 2011 15:45:38 +0100</pubDate>
            <guid isPermaLink="false">5069161</guid>        </item>
        <item>
            <title>Gait Abnormalities in Multiple Sclerosis: Pathogenesis, Evaluation, and Advances in Treatment</title>
            <link>http://www.medworm.com/index.php?rid=5061905&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb1l21v4024478430%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Multiple sclerosis (MS) is a demyelinating disease of the central nervous system characterized by episodic decline in various
 neurologic functions. Gait dysfunction in MS is distinguished by decreased gait speed, walking endurance, step length, cadence
 and joint motion, as well as increased metabolic cost of walking and increased variability of gait. Standardized clinical,
 timed, and patient-based measures can identify MS patients with gait dysfunction, and observational gait analysis, instrumented
 walkways, or three-dimensional gait analysis can help determine which problem underlies their gait dysfunction to help direct
 effective treatment. Exercise may ameliorate all types of gait dysfunction. In addition, gait dysfunction due to weakness
 may be alleviated by o...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5061905</comments>
            <pubDate>Thu, 21 Jul 2011 18:09:51 +0100</pubDate>
            <guid isPermaLink="false">5061905</guid>        </item>
        <item>
            <title>The Radiologically Isolated Syndrome: Look (Again) Before You Treat</title>
            <link>http://www.medworm.com/index.php?rid=5035977&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa13556270226655j%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The advent and wide use of magnetic resonance brain imaging has led to in the unexpected detection of lesions that appear
 typical of multiple sclerosis (MS) in otherwise asymptomatic patients. Several cohorts of patients with the “radiologically
 isolated syndrome (RIS)” have been studied mainly retrospectively, and a proportion of them do go on to have clinical symptoms
 of MS. This has led to the not infrequent clinical conundrum of whether or not to treat patients with MRI lesions suggestive
 of MS, given the knowledge that MS disease-modifying therapies work best when given early in the disease course. However,
 the decision to proactively treat patients with RIS is countered by the increasing risks associated with MS disease-modifying
 therapies as well as the...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5035977</comments>
            <pubDate>Tue, 12 Jul 2011 06:01:02 +0100</pubDate>
            <guid isPermaLink="false">5035977</guid>        </item>
        <item>
            <title>Role of Cerebrospinal Fluid and Plasma Biomarkers in the Diagnosis of Neurodegenerative Disorders and Mild Cognitive Impairment</title>
            <link>http://www.medworm.com/index.php?rid=5007666&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F24157548327x8r76%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Biomarkers are one type of laboratory testing being developed in response to the therapeutic imperative for diseases that
 cause cognitive impairment and dementia. The role of biomarkers is already transforming the organization and conduct of clinical
 trials, and if successful will likely contribute in the future to the medical management of patients with these diseases.
 Despite the obvious utility of practicality of blood- or urine-based biomarkers, so far results from these fluid compartments
 have not been reproducible. In contrast, substantial progress has been made in cerebrospinal fluid biomarkers. Here we review
 the stages of cerebrospinal fluid biomarker development for several common and unusual diseases that cause cognitive impairment
 and dementia, stressi...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5007666</comments>
            <pubDate>Mon, 04 Jul 2011 06:09:40 +0100</pubDate>
            <guid isPermaLink="false">5007666</guid>        </item>
        <item>
            <title>Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine</title>
            <link>http://www.medworm.com/index.php?rid=4968153&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F544q1rv87568j327%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Notwithstanding the availability of disease-modifying treatments including interferon-β, glatiramer acetate, and natalizumab,
 a considerable proportion of multiple sclerosis (MS) patients experience continued progression of disease, clinical relapses,
 disease activity on MRI, and adverse effects. Application of gene expression, proteomic or genomic approaches is universally
 accepted as a suitable strategy toward the identification of biomarkers with predictive value for beneficial/poor clinical
 response to therapy and treatment risks. This review focuses on recent progress in research on the pharmacogenomics of disease-modifying
 therapies for MS. Although MS drug response biomarkers are not yet routinely implemented in the clinic, the diversity of reported,
 promi...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4968153</comments>
            <pubDate>Thu, 23 Jun 2011 16:37:21 +0100</pubDate>
            <guid isPermaLink="false">4968153</guid>        </item>
        <item>
            <title>Advances in Epigenetics and Epigenomics for Neurodegenerative Diseases</title>
            <link>http://www.medworm.com/index.php?rid=4952537&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fqh260535032230mh%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In the post-genomic era, epigenetic factors—literally those that are “over” or “above” genetic ones and responsible for controlling
 the expression and function of genes—have emerged as important mediators of development and aging; gene-gene and gene-environmental
 interactions; and the pathophysiology of complex disease states. Here, we provide a brief overview of the major epigenetic
 mechanisms (ie, DNA methylation, histone modifications and chromatin remodeling, and non-coding RNA regulation). We highlight
 the nearly ubiquitous profiles of epigenetic dysregulation that have been found in Alzheimer’s and other neurodegenerative
 diseases. We also review innovative methods and technologies that enable the characterization of individual epigenetic modifi...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4952537</comments>
            <pubDate>Tue, 14 Jun 2011 06:02:19 +0100</pubDate>
            <guid isPermaLink="false">4952537</guid>        </item>
        <item>
            <title>Alternative Surgical Approaches in Epilepsy</title>
            <link>http://www.medworm.com/index.php?rid=4840943&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm5854461847w7q21%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The mainstay of epilepsy surgery is the resection of a presumed seizure focus or disruption of seizure propagation pathways.
 These approaches cannot be applied to all patients with medically refractory epilepsy (MRE). Since 1997, vagus nerve stimulation
 has been a palliative adjunct to the care of MRE patients. Deep brain stimulation (DBS) in select locations has been reported
 to reduce seizure frequency in small studies over the past three decades. Recently published results from the SANTE (Stimulation
 of the Anterior Nuclei of Thalamus for Epilepsy) trial—the first large-scale, randomized, double-blind trial of bilateral
 anterior thalamus DBS for MRE—demonstrate a significant reduction in seizure frequency with programmed stimulation. Another
 surgical altern...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4840943</comments>
            <pubDate>Mon, 16 May 2011 08:42:29 +0100</pubDate>
            <guid isPermaLink="false">4840943</guid>        </item>
        <item>
            <title>An Update on Psychogenic Movement Disorders</title>
            <link>http://www.medworm.com/index.php?rid=4820500&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw4q86kj5g67458h5%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Psychogenic movement disorders (PMD) and other conversion disorders (CD) with apparent neurologic signs (neurologic CD) plague
 patients and perplex physicians. Due to a lack of objective evidence of underlying brain lesions, CD were largely abandoned
 by neurologists and remained poorly understood psychiatric diagnoses throughout most of the 20th century. Modern neuroscience
 now supports increasingly comprehensive biological models for these complex disorders, definitively establishing their place
 in both neurology and psychiatry. Although it is often clinically useful to distinguish a movement disorder as either “organic”
 or “psychogenic,” this dichotomy is difficult to defend scientifically. Here we describe the neuroimaging and neurophysiologic
 evidence ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4820500</comments>
            <pubDate>Wed, 11 May 2011 05:51:21 +0100</pubDate>
            <guid isPermaLink="false">4820500</guid>        </item>
        <item>
            <title>Prolonged Postictal Suppression: A Potential Marker for Higher Risk of SUDEP, a Clue to Mechanism, or Both?</title>
            <link>http://www.medworm.com/index.php?rid=4770869&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu1348j34p127h137%2F</link>
            <description>Content Type Journal ArticlePages 1-2DOI 10.1007/s11910-011-0208-9Authors
		Carl W. Bazil, Department of Neurology, Columbia University College of Physicians and Surgeons, 710 West 168th Street, 7th Floor, New York, NY 10032, USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4770869</comments>
            <pubDate>Mon, 25 Apr 2011 16:43:45 +0100</pubDate>
            <guid isPermaLink="false">4770869</guid>        </item>
        <item>
            <title>Rescue Therapies for Seizures</title>
            <link>http://www.medworm.com/index.php?rid=4753454&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1u2878r5q1680414%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Most medical therapies for epilepsy consist of daily (or multiple-daily) dose, fixed-schedule, pharmacologic oral agents.
 Despite adherence, many patients continue to experience seizures. Various products have been discovered, designed, and marketed
 to serve as seizure-abortant therapies. These agents can be administered rapidly, as a “rescue” therapy, once a clinical seizure
 or cluster of seizures starts. Rescue medications are given as needed in an attempt to disrupt progression of a given seizure,
 and forestall what would otherwise be a more prolonged or more severe clinical event. Seizure-abortants also serve to aid
 in the management of seizure emergencies, such as prolonged, repetitive seizures, or status epilepticus. These compounds are
 not appropriate f...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4753454</comments>
            <pubDate>Thu, 21 Apr 2011 06:03:31 +0100</pubDate>
            <guid isPermaLink="false">4753454</guid>        </item>
        <item>
            <title>Of Monkeys and Men: Analysis of the Phase 2 Double-Blind, Sham-Surgery Controlled, Randomized Trial of AAV2-Neurturin Gene Therapy for Parkinson’s Disease</title>
            <link>http://www.medworm.com/index.php?rid=4744745&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fxu61q484n7220432%2F</link>
            <description>Content Type Journal ArticlePages 1-4DOI 10.1007/s11910-011-0206-yAuthors
		Daniel E. Huddleston, Department of Neurology, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30329, USAStewart A. Factor, Department of Neurology, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30329, USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4744745</comments>
            <pubDate>Wed, 20 Apr 2011 06:06:00 +0100</pubDate>
            <guid isPermaLink="false">4744745</guid>        </item>
        <item>
            <title>Gastrointestinal Features of Parkinson’s Disease</title>
            <link>http://www.medworm.com/index.php?rid=4723449&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy87q8x621761184m%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Gastrointestinal (GI) symptoms are among the most common nonmotor manifestations of Parkinson’s disease (PD), and they have
 many important ramifications for patients. The purpose of this review is to raise awareness of the full spectrum of GI symptoms
 in PD which include weight loss, sialorrhea, dysphagia, nausea, constipation, and defecatory dysfunction. We will discuss
 their practical significance, and outline a clear approach to their evaluation and management. A brief discussion about the
 impacts of commonly used medical and surgical PD therapies on GI symptom manifestation is also included.
 
 
	Content Type Journal ArticlePages 1-6DOI 10.1007/s11910-011-0204-0Authors
		Leslie J. Cloud, Emory University, 1841 Clifton Road NE, Atlanta, GA 30329, USAJames G. Gr...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4723449</comments>
            <pubDate>Fri, 15 Apr 2011 15:48:59 +0100</pubDate>
            <guid isPermaLink="false">4723449</guid>        </item>
        <item>
            <title>Mild Cognitive Impairment in Parkinson’s Disease</title>
            <link>http://www.medworm.com/index.php?rid=4723450&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv444217525111x18%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Prospective studies conducted during the last decade have shown that the majority of patients with Parkinson’s disease (PD)
 develop dementia. In addition, using a variety of definitions and methods, more recent research suggests that approximately
 a quarter of PD patients without dementia have mild cognitive impairment (PD-MCI). Furthermore, several studies have shown
 that approximately 20% have MCI even at time of diagnosis of PD. The typical cognitive deficits include visuospatial, attentional,
 and executive deficits, but memory deficits have also been shown. The etiology of PD-MCI is not known, but it is likely that
 mechanisms known to contribute to dementia in PD (ie, limbic and cortical Lewy bodies, amyloid plaques, and cholinergic deficits)
 play a role, in...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4723450</comments>
            <pubDate>Tue, 12 Apr 2011 21:26:43 +0100</pubDate>
            <guid isPermaLink="false">4723450</guid>        </item>
        <item>
            <title>An Update on Gene Therapy in Parkinson’s Disease</title>
            <link>http://www.medworm.com/index.php?rid=4709033&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm74437u679j45724%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Gene therapy for Parkinson’s disease (PD) may offer an alternative to current pharmacologic and surgical treatments; the former
 are limited by motor complications and non-motor adverse effects, and both by lack of neuroprotection. Three main strategies
 under investigation using gene transfer for targeted protein expression include improving availability of dopamine to the
 striatum with more continuous delivery, reducing activity in the subthalamic nucleus by locally inducing γ-aminobutyric acid
 expression, or protecting and restoring nigrostriatal neuronal function with trophic factor expression. This review summarizes
 the components of gene therapy for PD, the preclinical rationale for each strategy, data from the most recently published
 clinical trials using ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4709033</comments>
            <pubDate>Mon, 11 Apr 2011 05:37:49 +0100</pubDate>
            <guid isPermaLink="false">4709033</guid>        </item>
        <item>
            <title>What Is the Role of Genetic Testing in Movement Disorders Practice?</title>
            <link>http://www.medworm.com/index.php?rid=4693055&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F11115222704j5205%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Genetic testing holds many promises in movement disorders, but also pitfalls that require careful consideration for meaningful
 results. These include the primary indication for testing in the first place, concerns regarding the implications of symptomatic,
 presymptomatic, and susceptibility testing, the mutation frequency in the gene of interest, the general lack of neuroprotective
 treatment options for neurodegenerative movement disorders, the prognosis of the condition diagnosed, and patient confidentiality
 concerns. Furthermore, new technical achievements and the available technical expertise, feasibility of specific gene testing,
 and its coverage through a health insurance carrier should be considered. Guidelines for testing have been established by
 some disea...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4693055</comments>
            <pubDate>Tue, 05 Apr 2011 10:02:35 +0100</pubDate>
            <guid isPermaLink="false">4693055</guid>        </item>
        <item>
            <title>Antiepileptic Drugs and Neurodevelopment: An Update</title>
            <link>http://www.medworm.com/index.php?rid=4693054&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F936w452h8345n285%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In utero exposure to some antiepileptic drugs (AEDs) is associated with an increased risk of impaired cognitive development.
 Specifically, valproate and polytherapy exposure are each associated with an increased risk of cognitive impairment in children
 compared with other antiepileptic medications. The data regarding the risk to neurocognitive development imposed by maternal
 use of other AEDs are conflicting or insufficient at this time to draw definitive conclusions. Behavioral dysfunction including
 autistic spectrum disorder is also associated with maternal use of AEDs during pregnancy. Whether treatment with AEDs during
 childhood permanently affects cognitive neurodevelopment is yet to be determined.
 
 
	Content Type Journal ArticlePages 1-5DOI 10.1007/s11910-0...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4693054</comments>
            <pubDate>Tue, 05 Apr 2011 10:02:35 +0100</pubDate>
            <guid isPermaLink="false">4693054</guid>        </item>
        <item>
            <title>Genomic Profiles of Glioma</title>
            <link>http://www.medworm.com/index.php?rid=4693053&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fhm557m0727373255%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Recent large-scale genomic profiling studies of glioma have yielded a proliferation of candidate subclasses, biomarkers and
 therapeutic targets for investigation. Some findings, such as that of IDH mutation in low-grade gliomas and secondary glioblastoma
 (GBM), fit well into established notions of different routes of gliomagenesis. Other results, such as the division of primary
 GBM based on signaling pathway alterations, suggest new pathogenetic routes with implications for treatment. The analysis
 of this data is still in the early stage. Nonetheless, several preliminary findings merit consideration in the development
 and interpretation of current clinical trials.
 
 
	Content Type Journal ArticlePages 1-7DOI 10.1007/s11910-011-0198-7Authors
		Cameron Brennan, Huma...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4693053</comments>
            <pubDate>Tue, 05 Apr 2011 10:02:35 +0100</pubDate>
            <guid isPermaLink="false">4693053</guid>        </item>
        <item>
            <title>Biofeedback and Epilepsy</title>
            <link>http://www.medworm.com/index.php?rid=4693056&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg284g857571kh872%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Biofeedback is a noninvasive behavioral treatment that enables a patient to gain volitional control over a physiological process.
 As a treatment for epilepsy, biofeedback interventions were explored from as early as the 1970s, concentrating on sensory
 motor rhythm (SMR) as a neurophysiologic parameter. Whereas SMR biofeedback aims to modulate frequency components of the electroencephalography
 (EEG), slow cortical potential (SCP) biofeedback (which was introduced in the 1990s) focuses on the regulation of the amplitude
 of cortical potential changes (DC shift). In its application to epilepsy, biofeedback using galvanic skin response (GSR),
 an electrodermal measure of sympathetic activity, is a relatively new cost-effective methodology. The present article first
 revi...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4693056</comments>
            <pubDate>Tue, 05 Apr 2011 10:02:34 +0100</pubDate>
            <guid isPermaLink="false">4693056</guid>        </item>
        <item>
            <title>Differential Diagnosis of Chorea</title>
            <link>http://www.medworm.com/index.php?rid=4693057&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7841702131jw77v6%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Chorea is a common movement disorder that can be caused by a large variety of structural, neurochemical (including pharmacologic),
 or metabolic disturbances to basal ganglia function, indicating the vulnerability of this brain region. The diagnosis is rarely
 indicated by the simple phenotypic appearance of chorea, and can be challenging, with many patients remaining undiagnosed.
 Clues to diagnosis may be found in the patient’s family or medical history, on neurologic examination, or upon laboratory
 testing and neuroimaging. Increasingly, advances in genetic medicine are identifying new disorders and expanding the phenotype
 of recognized conditions. Although most therapies at present are supportive, correct diagnosis is essential for appropriate
 genetic counselin...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4693057</comments>
            <pubDate>Tue, 05 Apr 2011 10:02:32 +0100</pubDate>
            <guid isPermaLink="false">4693057</guid>        </item>
        <item>
            <title>Prognosis of Intractable Epilepsy: Is Long-Term Seizure Freedom Possible with Medical Management?</title>
            <link>http://www.medworm.com/index.php?rid=4683928&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1070h53322782775%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Until recently, very little data existed on long-term seizure prognosis of patients with intractable epilepsy. We review recent
 work that assessed seizure remission in patients with intractable epilepsy during medical management. Recent prevalence cohort
 studies among adults with longstanding intractable epilepsy have demonstrated notable proportions of patients attaining at
 least 1-year seizure freedom, ranging from more than 10% to nearly 30% of patients, when followed for mean duration of 18&amp;nbsp;months
 to 6&amp;nbsp;years. Additionally, a recent prospective cohort study of pediatric-onset intractable epilepsy (followed prospectively
 for seizure outcome from onset of intractability) revealed minimum 1-year seizure remission among more than half of study
 patients. D...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4683928</comments>
            <pubDate>Sat, 02 Apr 2011 05:54:08 +0100</pubDate>
            <guid isPermaLink="false">4683928</guid>        </item>
        <item>
            <title>Hormonal Therapy for Epilepsy</title>
            <link>http://www.medworm.com/index.php?rid=4669971&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fvn7071k27773949l%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In 2011, there are greater than 20 antiepileptic medications available. These medications work by modulating neuronal excitability.
 Reproductive hormones have been found to have a role in the pathogenesis and treatment of seizures by also altering neuronal
 excitability, especially in women with catamenial epilepsy. The female reproductive hormones have in general opposing effects
 on neuronal excitability; estrogens generally impart a proconvulsant neurophysiologic tone, whereas the progestogens have
 anticonvulsant effects. It follows then that fluctuations in the levels of serum progesterone and estrogen throughout a normal
 reproductive cycle bring about an increased or decreased risk of seizure occurrence based upon the serum estradiol/progesterone
 ratio. Therefo...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4669971</comments>
            <pubDate>Wed, 30 Mar 2011 23:53:42 +0100</pubDate>
            <guid isPermaLink="false">4669971</guid>        </item>
        <item>
            <title>Alzheimer’s Genetics in the GWAS Era: A Continuing Story of ‘Replications and Refutations’</title>
            <link>http://www.medworm.com/index.php?rid=4663714&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff875645430247116%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;After a decade of intensive investigation but only few replicable results, Alzheimer’s disease (AD) genetics research is slowly
 picking up pace. This is mostly owing to the completion of several genome-wide association studies (GWAS), which have suggested
 the existence of over three dozen potential new AD susceptibility genes. Although only a handful of these could be confirmed
 in subsequent independent replication efforts to date, this success rate is still much higher than in the pre-GWAS era. This
 review provides a brief summary of the principal methodologic advances in genetics research of the past decade, followed by
 a description of the most compelling findings that these advances have unearthed in AD. The paper closes with a discussion
 of the persistent m...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4663714</comments>
            <pubDate>Tue, 29 Mar 2011 07:04:03 +0100</pubDate>
            <guid isPermaLink="false">4663714</guid>        </item>
        <item>
            <title>Epilepsy and Autism: Neurodevelopmental Perspective</title>
            <link>http://www.medworm.com/index.php?rid=4631339&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx5q42m346n055563%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Epilepsy and autism coexist in up to 20% of children with either disorder. Current studies suggest that a frequent co-occurring
 condition in epilepsy and autism is intellectual disability, which shows a very high prevalence in those with both autism
 and epilepsy. In addition, these recent studies suggest that early-onset seizures may index a group of infants at high risk
 for developing autism, usually with associated intellectual deficits. In this review we discuss recent advances in the conceptualization
 of shared anatomical and molecular mechanisms that may account for the coexistence of epilepsy, autism, and intellectual disability.
 A major contribution to our improved understanding of the relationship among these three phenotypes is the discovery of multiple
 g...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4631339</comments>
            <pubDate>Mon, 21 Mar 2011 18:56:25 +0100</pubDate>
            <guid isPermaLink="false">4631339</guid>        </item>
        <item>
            <title>Current State of Our Knowledge on Brain Tumor Epidemiology</title>
            <link>http://www.medworm.com/index.php?rid=4501411&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe7163wm7v92p3264%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The overall incidence of brain tumors for benign and malignant tumors combined is 18.71 per 100,000 person-years; 11.52 per
 100,000 person-years for benign tumors and 7.19 per 100,000 person-years for malignant tumors. Incidence, response to treatment,
 and survival after diagnosis vary greatly by age at diagnosis, histologic type of tumor, and degree of neurologic compromise.
 The only established environmental risk factor for brain tumors is ionizing radiation exposure. Exposure to radiofrequency
 electromagnetic fields via cell phone use has gained a lot of attention as a potential risk factor for brain tumor development.
 However, studies have been inconsistent and inconclusive due to systematic differences in study designs and difficulty of
 accurately measuring c...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4501411</comments>
            <pubDate>Fri, 18 Feb 2011 17:24:37 +0100</pubDate>
            <guid isPermaLink="false">4501411</guid>        </item>
        <item>
            <title>Molecular Mechanisms of PINK1-Related Neurodegeneration</title>
            <link>http://www.medworm.com/index.php?rid=4501412&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6474667764740461%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;PINK1 is a mitochondrially targeted kinase that has been linked to a rare monogenic form of Parkinson’s disease (PD), a common
 neurodegenerative disease characterized by the degeneration of selected dopaminergic neurons. Intensive research using many
 model systems has clearly established a fundamental role for PINK1 in preventing mitochondrial dysfunction—a key mechanism
 long thought to play a central role in PD pathogenesis. Current hypotheses propose PINK1’s important functions involve mitophagy,
 mitochondrial calcium buffering, and mitochondrial quality control. Furthermore, recent findings have revealed that PINK1’s
 functions are likely regulated by a complex mechanism that includes regulated mitochondrial import and intramembrane proteolysis
 to influe...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4501412</comments>
            <pubDate>Fri, 18 Feb 2011 06:48:38 +0100</pubDate>
            <guid isPermaLink="false">4501412</guid>        </item>
        <item>
            <title>NMDA Receptor Antibody Encephalitis</title>
            <link>http://www.medworm.com/index.php?rid=4501413&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh37042862h264480%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 N-methyl-d-aspartate receptor (NMDAR) antibody encephalitis is a recently described immunotherapy-responsive panencephalitis with characteristic
 features that include a psychiatric onset and a later movement disorder. This entity was first described as a paraneoplastic
 phenomenon in young women with ovarian teratomata. However, more recently it has become clear that the majority of patients,
 particularly children, do not harbor a tumor and that males can also be affected. With the development of the NMDAR antibody
 assay, now available worldwide, a few patients with classical limbic encephalitis and early psychosis and epilepsy have also
 been found to harbor these antibodies. Early diagnosis followed by immunotherapies and tumor removal, when relevant, expedite
 r...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4501413</comments>
            <pubDate>Thu, 17 Feb 2011 17:03:29 +0100</pubDate>
            <guid isPermaLink="false">4501413</guid>        </item>
        <item>
            <title>Recent Advances in the Genetics of Hereditary Axonal Sensory-Motor Neuropathies Type 2</title>
            <link>http://www.medworm.com/index.php?rid=4494765&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk771374050vrk86n%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Hereditary axonal motor and sensory neuropathies or Charcot-Marie-Tooth disease type 2 (CMT2) are characterized clinically
 by distal muscle weakness and atrophy, sensory loss, and foot deformities. Conduction velocities are usually in the normal
 range or mildly slowed. The majority of CMT2 are autosomal-dominant but autosomal-recessive forms have been described. The
 number of genes associated with CMT2 have significantly increased in the past decade, with the gene causing CMT2C/SPSMA being
 the last one discovered. More than 10 genes are now associated with different subtypes of CMT2, which are classified from
 CMT2A to CMT2N. These genes have distinct functions, but some appear to be involved in common biological pathways, therefore,
 providing important clues for u...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4494765</comments>
            <pubDate>Wed, 16 Feb 2011 06:59:37 +0100</pubDate>
            <guid isPermaLink="false">4494765</guid>        </item>
        <item>
            <title>Adult Primary Intradural Spinal Cord Tumors: A Review</title>
            <link>http://www.medworm.com/index.php?rid=4494766&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft5n047322k233645%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Primary spinal cord tumors constitute 2% to 4% of all central nervous system neoplasms and are characterized based on their
 location as intramedullary, intradural extramedullary, and extradural. A contemporary literature review of primary intradural
 spinal cord tumors was performed. Among intramedullary tumors, ependymomas are more common and often can be surgically resected.
 However, astrocytomas infiltrate the spinal cord and complete resection is rare. Intradural extramedullary tumors include
 schwannomas, neurofibromas, and meningiomas and are usually amenable to surgical resection. Radiotherapy is reserved for malignant
 variants and recurrent gliomas, whereas chemotherapy is administered for recurrent primary spinal cord tumors without surgical
 or radiotherapy...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4494766</comments>
            <pubDate>Wed, 16 Feb 2011 06:59:36 +0100</pubDate>
            <guid isPermaLink="false">4494766</guid>        </item>
        <item>
            <title>Neurosurgery for Brain Tumors: Update on Recent Technical Advances</title>
            <link>http://www.medworm.com/index.php?rid=4494767&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fjj378353631u8451%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Advances in diagnostic imaging modalities and improved access to specialty care have led directly to an increased diagnosis
 of both metastatic and primary brain tumors. As technology has improved, so has the ability to treat this larger patient population.
 Diffusion tensor imaging (DTI) has recently shown the potential to aid in histologic diagnosis as well as to identify local
 brain invasion outside of that readily identifiable by conventional MRI. Similar to DTI, functional MRI provides a noninvasive
 means of delineating tumor margin from eloquent cortex and aids in preoperative surgical planning. As the literature shows
 increasing support for the advantages of extensive resection in glioma patients, modalities that aid in this regard are displaying
 increased im...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4494767</comments>
            <pubDate>Wed, 16 Feb 2011 06:59:35 +0100</pubDate>
            <guid isPermaLink="false">4494767</guid>        </item>
        <item>
            <title>The Pathophysiologic Basis of Secondary Narcolepsy and Hypersomnia</title>
            <link>http://www.medworm.com/index.php?rid=4459618&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F804x57081l740j1r%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The symptoms of narcolepsy can occur during the course of other neurologic conditions (ie, symptomatic narcolepsy). Inherited
 disorders, tumors, and head trauma were the three most frequent causes for symptomatic narcolepsy. Other causes include multiple
 sclerosis (MS), vascular disorders, and encephalitis. Cerebrospinal fluid hypocretin-1 measures were carried out in some recent
 cases with symptomatic narcolepsy, and moderate decreases in hypocretin levels were seen in a large majority of these cases.
 Excessive daytime sleepiness (EDS) in these symptomatic cases was sometimes reversible with an improvement of the causative
 neurologic disorder and with an improvement of the hypocretin (orexin) status. Recently, we found that several symptomatic
 narcoleptic cases w...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4459618</comments>
            <pubDate>Mon, 07 Feb 2011 06:40:19 +0100</pubDate>
            <guid isPermaLink="false">4459618</guid>        </item>
        <item>
            <title>Genetics of Neurodegeneration with Brain Iron Accumulation</title>
            <link>http://www.medworm.com/index.php?rid=4441896&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk807169638217655%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The condition originally called Hallervorden-Spatz syndrome is a collection of related disorders involving abnormal iron accumulation
 in the basal ganglia, usually manifesting with a movement disorder. To date, mutations in the following genes have been associated
 with neurodegeneration with brain iron accumulation (NBIA) phenotypes: PANK2, PLA2G6, FA2H, ATP13A2, C2orf37, CP, and FTL. This collection, now classified under the umbrella term NBIA, continues to evolve as new genes and associated phenotypes
 are recognized. As this body of information continues to grow, better approaches to diagnosis and treatment have become available.
 Continued investigations of the underlying pathogenesis of disease, with a focus on lipid, iron, and energy metabolism, will
 lead to th...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4441896</comments>
            <pubDate>Tue, 01 Feb 2011 08:39:30 +0100</pubDate>
            <guid isPermaLink="false">4441896</guid>        </item>
        <item>
            <title>Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence</title>
            <link>http://www.medworm.com/index.php?rid=4428786&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm8038v5j6012v257%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Antiangiogenic treatment has recently become an integral part of modern cancer therapy targeting the vasculature of numerous
 aggressive malignancies including glioblastoma. There is preclinical evidence that antiangiogenic therapies promote glioma
 cell invasiveness. In clinical series, upon progression on antiangiogenic therapy with the vascular endothelial growth factor–directed
 antibody bevacizumab (BEV), glioblastoma has been reported to display a more infiltrative pattern of recurrence. This distant
 spread at recurrence or progression and a gliomatosis cerebri-like growth pattern is best detectable on fluid-attenuated inversion
 recovery MRI. The frequency of up to 20% to 30% of such a pattern in BEV-treated patients is higher than expected to occur
 without B...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4428786</comments>
            <pubDate>Mon, 31 Jan 2011 07:31:51 +0100</pubDate>
            <guid isPermaLink="false">4428786</guid>        </item>
        <item>
            <title>Modeling Neurodegeneration in Zebrafish</title>
            <link>http://www.medworm.com/index.php?rid=4418884&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj21t6v20447g55l5%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The zebrafish, Danio rerio, has been established as an excellent vertebrate model for the study of developmental biology and gene function. It also
 has proven to be a valuable model to study human diseases. Here, we reviewed recent publications using zebrafish to study
 the pathology of human neurodegenerative diseases including Parkinson’s, Huntington’s, and Alzheimer’s. These studies indicate
 that zebrafish genes and their human homologues have conserved functions with respect to the etiology of neurodegenerative
 diseases. The characteristics of the zebrafish and the experimental approaches to which it is amenable make this species a
 useful complement to other animal models for the study of pathologic mechanisms of neurodegenerative diseases and for the
 scr...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418884</comments>
            <pubDate>Thu, 27 Jan 2011 01:08:36 +0100</pubDate>
            <guid isPermaLink="false">4418884</guid>        </item>
        <item>
            <title>Advances in Primary CNS Lymphoma: Randomized Clinical Trials of Chemotherapy and Whole-Brain Radiotherapy</title>
            <link>http://www.medworm.com/index.php?rid=4418883&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft33t33p0616821k6%2F</link>
            <description>Content Type Journal ArticlePages 1-3DOI 10.1007/s11910-011-0183-1Authors
		Lauren E. Abrey, Unterer Rheinweg 56, CH 4057 Basel, Switzerland
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418883</comments>
            <pubDate>Thu, 27 Jan 2011 01:08:36 +0100</pubDate>
            <guid isPermaLink="false">4418883</guid>        </item>
        <item>
            <title>[Without Title]</title>
            <link>http://www.medworm.com/index.php?rid=4371681&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp641150831204816%2F</link>
            <description>Content Type Journal Article

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4371681</comments>
            <pubDate>Thu, 20 Jan 2011 01:09:13 +0100</pubDate>
            <guid isPermaLink="false">4371681</guid>        </item>
        <item>
            <title>Migraine Chronification</title>
            <link>http://www.medworm.com/index.php?rid=4377363&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ftjl81m745t568lk7%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Migraine is a disorder with variable natural history. In some sufferers, migraine evolves over time into a state of headaches
 on more days than not. This process of migraine chronification is poorly understood, but risk factors have been clearly identified.
 Herein, we first discuss the role of heritability and of genetic risk factors on migraine chronification. We follow with a
 discussion of the role of comorbid conditions and environmental exposures. We suggest that clinicians consider risk factor
 modification as part of migraine management, aspiring to not just relieve current pain and disability, but to avoid migraine
 progression. Reducing attack frequency, avoiding medication overuse, appropriately using preventive drugs and behavioral therapies,
 and encouragi...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4377363</comments>
            <pubDate>Mon, 17 Jan 2011 20:40:22 +0100</pubDate>
            <guid isPermaLink="false">4377363</guid>        </item>
        <item>
            <title>Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy</title>
            <link>http://www.medworm.com/index.php?rid=4360762&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1v427616p5126426%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Bevacizumab is thought to normalize tumor vasculature and restore the blood–brain barrier, decreasing enhancement and peritumoral
 edema. Conventional measurements of tumor response rely upon dimensions of enhancing tumor. After bevacizumab treatment, glioblastomas
 are more prone to progress as nonenhancing tumor. The RANO (Response Assessment in Neuro-Oncology) criteria for glioma response
 use fluid-attenuated inversion recovery (FLAIR)/T2 hyperintensity as a surrogate for nonenhancing tumor; however, nonenhancing
 tumor can be difficult to differentiate from other causes of FLAIR/T2 hyperintensity (eg, radiation-induced gliosis). Due
 to these difficulties, recent efforts have been directed toward identifying new biomarkers that either predict treatment response
 ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4360762</comments>
            <pubDate>Sat, 15 Jan 2011 00:57:12 +0100</pubDate>
            <guid isPermaLink="false">4360762</guid>        </item>
        <item>
            <title>The Sleep Manifestations of Frontal Lobe Epilepsy</title>
            <link>http://www.medworm.com/index.php?rid=4360763&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8638765357173166%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Frontal lobe seizures have a tendency to occur from sleep, and in some cases occur exclusively (or almost exclusively) from
 sleep; these individuals are said to have nocturnal frontal lobe epilepsy (NFLE). NFLE can be difficult to distinguish clinically
 from various other sleep disorders, particularly parasomnias, which also present with paroxysmal motor activity in sleep.
 Here, the manifestations of frontal lobe epilepsy are reviewed in detail, with particular reference to the influence of sleep
 and the characteristics of NFLE. Key aspects of differential diagnosis are also considered, and the underlying mechanisms
 involved in NFLE discussed.
 
 
	Content Type Journal ArticlePages 1-9DOI 10.1007/s11910-011-0180-4Authors
		Christopher P. Derry, Department of Clinic...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4360763</comments>
            <pubDate>Sat, 15 Jan 2011 00:57:10 +0100</pubDate>
            <guid isPermaLink="false">4360763</guid>        </item>
        <item>
            <title>Newly Postulated Neurodevelopmental Risks of Pediatric Anesthesia</title>
            <link>http://www.medworm.com/index.php?rid=4342933&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy5t73572627k7082%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Recent animal and human studies have raised concern that exposure to anesthetic agents in children may cause neuronal damage
 and be associated with adverse neurodevelopmental outcomes. Exposure of young animals to anesthetic agents above threshold
 doses and durations during a critical neurodevelopmental window in the absence of concomitant painful stimuli causes widespread
 neuronal apoptosis and subsequent abnormal behaviors. The relevance of such animal data to humans is unknown. Untreated neonatal
 pain and stress also are associated with enhanced neuronal death and subsequent maladaptive behaviors, which can be prevented
 by exposure to these same anesthetic agents. Retrospective observational human studies have suggested a dose-dependent association
 between mult...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4342933</comments>
            <pubDate>Tue, 11 Jan 2011 07:34:19 +0100</pubDate>
            <guid isPermaLink="false">4342933</guid>        </item>
        <item>
            <title>Molecular Genetics of Neuronal Migration Disorders</title>
            <link>http://www.medworm.com/index.php?rid=4342934&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fxh3630871l258224%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cortical malformations associated with defects in neuronal migration result in severe developmental consequences including
 intractable epilepsy and intellectual disability. Genetic causes of migration defects have been identified with the advent
 and widespread use of high-resolution MRI and genetic techniques. Thus, the full phenotypic range of these genetic disorders
 is becoming apparent. Genes that cause lissencephaly, pachygyria, subcortical band heterotopia, and periventricular nodular
 heterotopias have been defined. Many of these genes are involved in cytoskeletal regulation including the function of microtubules
 (LIS1, TUBA1A,TUBB3, and DCX) and of actin (FilaminA). Thus, the molecular pathways regulating neuronal migration including the cytoskeletal pathways...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4342934</comments>
            <pubDate>Mon, 10 Jan 2011 20:06:56 +0100</pubDate>
            <guid isPermaLink="false">4342934</guid>        </item>
        <item>
            <title>Hormonal Manipulation Strategies in the Management of Menstrual Migraine and Other Hormonally Related Headaches</title>
            <link>http://www.medworm.com/index.php?rid=4322338&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8042418k28845106%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Menstrual migraine and other hormonally related headaches are common in women. Falling estrogen levels or estrogen withdrawal
 after periods of sustained higher levels can trigger migraine. It makes sense to target this trigger for management of hormonally
 related headaches, particularly when nonhormonal strategies have been unsuccessful. Decision making regarding the use of hormonal
 contraception and menopausal hormone therapy is complex and commonly driven by other factors, but hormonal manipulation can
 potentially improve the course of migraine. Providers caring for migraineurs are appropriately concerned about stroke risk.
 Estrogen-containing hormonal contraceptives are relatively contraindicated for women who have migraine with aura. Postmenopausal
 hormone the...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4322338</comments>
            <pubDate>Wed, 05 Jan 2011 06:48:52 +0100</pubDate>
            <guid isPermaLink="false">4322338</guid>        </item>
        <item>
            <title>Moyamoya Disease and Surgical Intervention</title>
            <link>http://www.medworm.com/index.php?rid=4302055&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg749p385k6146j07%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Stroke is an increasingly recognized cause of morbidity in the pediatric population. The incidence of ischemic stroke is 1.2
 per 100,000 children. There are many known etiologies of childhood cerebral ischemia but moyamoya is one of the only ischemic
 conditions of childhood that can be effectively treated with surgery. Moyamoya disease is by definition idiopathic, whereas
 moyamoya syndrome refers to a similar disease course in conjunction with a known predisposing condition. The clinical manifestations
 and disease progression are similar. Furthermore, surgical treatment has been shown to be efficacious and safe in the treatment
 of moyamoya.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0173-8Authors
		Jay W. Rhee, Department of Neurosurgery, Georgetown Un...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4302055</comments>
            <pubDate>Wed, 29 Dec 2010 17:14:15 +0100</pubDate>
            <guid isPermaLink="false">4302055</guid>        </item>
        <item>
            <title>Treatment of Refractory Status Epilepticus in Childhood</title>
            <link>http://www.medworm.com/index.php?rid=4285041&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu4221226044v57u4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Refractory status epilepticus (RSE) is characterized by a prolonged seizure that persists despite adequate initial management.
 RSE accounts for almost one quarter of all status epilepticus and carries significant risk for morbidity and mortality. Treatment
 varies widely between institutions regarding medication choice, dose, and monitoring. Several agents including nonanesthetic
 antiepileptic drugs (AEDs), anesthetic AEDs, enteral AEDs, and other therapies have been used in RSE. We review the current
 treatment strategies for RSE, focusing on patient selection, monitoring, optimal dosing and administration of medications,
 efficacy, adverse effects, and treatment duration.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0170-yAuthors
		John M. Schreiber, Depa...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4285041</comments>
            <pubDate>Tue, 21 Dec 2010 07:21:34 +0100</pubDate>
            <guid isPermaLink="false">4285041</guid>        </item>
        <item>
            <title>Hypocretin and Its Emerging Role as a Target for Treatment of Sleep Disorders</title>
            <link>http://www.medworm.com/index.php?rid=4272161&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg631338118v2v200%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The neuropeptides hypocretin-1 and -2 (orexin A and B) are critical in the regulation of arousal and maintenance of wakefulness.
 Understanding the role of the hypocretin system in sleep/wake regulation has come from narcolepsy-cataplexy research. Deficiency
 of hypocretin results in loss of sleep/wake control with consequent unstable transitions from wakefulness into non–rapid eye
 movement (REM) and REM sleep, and clinical manifestations including daytime hypersomnolence, sleep attacks, and cataplexy.
 The hypocretin system regulates sleep/wake control through complex interactions between monoaminergic/cholinergic wake–promoting
 and GABAergic sleep–promoting neuronal systems. Research for the hypocretin agonist and the hypocretin antagonist for the
 treatment o...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4272161</comments>
            <pubDate>Fri, 17 Dec 2010 17:42:00 +0100</pubDate>
            <guid isPermaLink="false">4272161</guid>        </item>
        <item>
            <title>High-Flow Oxygen: A Gladly Received Fresh Look at an Old but Effective Abortive Treatment for Cluster Headache</title>
            <link>http://www.medworm.com/index.php?rid=4272162&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu741q45111043003%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s11910-010-0171-xAuthors
		Ivan Garza, Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4272162</comments>
            <pubDate>Thu, 16 Dec 2010 06:55:00 +0100</pubDate>
            <guid isPermaLink="false">4272162</guid>        </item>
        <item>
            <title>Paraneoplastic Neurologic Disorders in Children</title>
            <link>http://www.medworm.com/index.php?rid=4272163&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb7v571722r030736%2F</link>
            <description>This article reviews the presenting symptoms,
 immunology, long-term sequelae, and management options for paraneoplastic neurologic syndromes, focusing on those most commonly
 reported in children: opsoclonus-myoclonus ataxia, limbic encephalitis, and anti-NMDAR encephalitis. The child neurologist
 plays an important role in recognizing these disorders, initiating a tumor search, and directing ongoing treatment and management
 of neurologic symptoms after oncologic treatment is complete. Given the rarity of these conditions, multisite collaborative
 efforts are needed to develop standardized approaches to characterization and treatment.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0169-4Authors
		Elizabeth M. Wells, Department of Neurology, Children’s National Medical Center, ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4272163</comments>
            <pubDate>Thu, 16 Dec 2010 06:54:59 +0100</pubDate>
            <guid isPermaLink="false">4272163</guid>        </item>
        <item>
            <title>The Association of Pituitary Tumors and Headache</title>
            <link>http://www.medworm.com/index.php?rid=4230082&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0447u817254r3338%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Pituitary tumors may give rise to headache via numerous mechanisms. The traditional explanation for headache is dural stretch
 and cavernous sinus invasion, although this is not borne out by clinical studies. Certain functional pituitary tumors are
 associated with headache, notably growth hormone and prolactin-secreting tumors. The observation that somatostatin analogues
 can have a dramatic analgesic effect in acromegaly suggests that biochemical properties of the tumor may be important. The
 genetic predisposition of the patient to primary headache also determines whether headache occurs with pituitary tumors. This
 article attempts to outline the clinical features, management strategies, and key academic questions regarding the subject
 of pituitary tumors and heada...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4230082</comments>
            <pubDate>Fri, 03 Dec 2010 06:59:56 +0100</pubDate>
            <guid isPermaLink="false">4230082</guid>        </item>
        <item>
            <title>Risk Stratification of Medulloblastoma: A Paradigm for Future Childhood Brain Tumor Management Strategies</title>
            <link>http://www.medworm.com/index.php?rid=4230083&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp71g247829164269%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s11910-010-0168-5Authors
		Roger J. Packer, Center for Neuroscience and Behavioral Medicine, Gilbert Neurofibromatosis Institute, Brain Tumor Institute, Children’s National Medical Center, 111 Michigan Avenue, NW, Washington, DC 20010, USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4230083</comments>
            <pubDate>Fri, 03 Dec 2010 06:59:55 +0100</pubDate>
            <guid isPermaLink="false">4230083</guid>        </item>
        <item>
            <title>Ocular and Orbital Pain for the Headache Specialist</title>
            <link>http://www.medworm.com/index.php?rid=4230084&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7225421m65237010%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Ocular pain is most commonly associated with redness and inflammation; however, eye pain can also occur in the absence of
 grossly visible pathology. Pain in the quiet eye can be the first sign of a number of threatening conditions. Many of these
 conditions such as intermittent angle closure glaucoma, carotid artery dissection, idiopathic intracranial hypertension, and
 giant cell arteritis can lead to permanent vision loss or blindness. In this review, ocular history and examination techniques
 are summarized. The article also reviews pertinent ocular, orbital, referred, and other causes of eye pain in the quiet eye.
 The neurologist and headache specialist should recognize when consultation with an ophthalmologist is necessary.
 
 
	Content Type Journal ArticleDOI 10...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4230084</comments>
            <pubDate>Fri, 03 Dec 2010 06:59:54 +0100</pubDate>
            <guid isPermaLink="false">4230084</guid>        </item>
        <item>
            <title>Furthering the Understanding of the Pathophysiology of Narcolepsy</title>
            <link>http://www.medworm.com/index.php?rid=4230085&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk6jknh5uh7605m60%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s11910-010-0165-8Authors
		Michael J. Thorpy, Sleep-Wake Disorders Center, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4230085</comments>
            <pubDate>Thu, 02 Dec 2010 07:09:49 +0100</pubDate>
            <guid isPermaLink="false">4230085</guid>        </item>
        <item>
            <title>Cervicogenic Headache: A Real Headache</title>
            <link>http://www.medworm.com/index.php?rid=4230086&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F33q1461134064265%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Although theories regarding headache originating in the neck have existed for more than 150&amp;nbsp;years, the term “cervicogenic
 headache” originated in 1983. Early descriptions pinpoint the characteristic symptoms as dizziness, visual disturbances, tinnitus,
 and “posterior” headache, conceivably as a consequence of arthrosis, infliction upon the vertebral artery, or with a “migrainous”
 background and occurring in “advanced age.” Cervicogenic headache (mean age of onset, 33&amp;nbsp;years) displays a somewhat different
 picture: unilateral headache, starting posteriorly, but advancing to the frontal area, most frequently the main site of pain;
 usually accompanied by ipsilateral arm discomfort, reduced range of motion in the neck, and mechanical precipitati...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4230086</comments>
            <pubDate>Thu, 02 Dec 2010 07:09:48 +0100</pubDate>
            <guid isPermaLink="false">4230086</guid>        </item>
        <item>
            <title>Current Status of Antiplatelet Agents to Prevent Stroke</title>
            <link>http://www.medworm.com/index.php?rid=4200412&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp7817773587556g1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Stroke is one of the leading causes of disability; most are due to atherothrombotic mechanisms. About one third of ischemic
 strokes are preceded by other stroke or transient ischemic attacks. Stroke survivors are at high risk for vascular events
 (i.e., cerebrovascular and cardiovascular). Prevention of recurrent stroke and other major vascular events can be accomplished
 by control of risk factors. Nonetheless, the use of antiplatelet agents remains the fundamental component of secondary stroke
 prevention strategy in patients with noncardioembolic disease. Currently, the uses of aspirin, clopidogrel, or aspirin plus
 extended-release dipyridamole are valid alternatives for stroke or transient ischemic attack patients. To maximize the beneficial
 effects of these agen...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4200412</comments>
            <pubDate>Mon, 22 Nov 2010 13:22:33 +0100</pubDate>
            <guid isPermaLink="false">4200412</guid>        </item>
        <item>
            <title>Asymptomatic Sleep Abnormalities Are a Common Early Feature in Patients with Huntington’s Disease</title>
            <link>http://www.medworm.com/index.php?rid=4189942&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn3nh777qk1w16361%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Huntington’s disease (HD) is a fatal neurodegenerative disease characterized by motor, cognitive, and psychiatric disturbance.
 In this article, we used polysomnography, actigraphy and a variety of validated questionnaires to ascertain the extent to
 which sleep changes are identifiable and measurable in mild stage HD, and importantly, to see whether patients are negatively
 impacted by the changes in their sleep. We found significant differences in sleep architecture and sleep efficiency in patients
 compared with controls using polysomnography. However, patient scores on the Functional Outcomes of Sleep Questionnaire, Medical
 Outcomes of Sleep Scale, and Epworth Sleepiness Scale were not significantly different to controls. These results suggest
 that although mark...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4189942</comments>
            <pubDate>Fri, 19 Nov 2010 17:06:01 +0100</pubDate>
            <guid isPermaLink="false">4189942</guid>        </item>
        <item>
            <title>Stroke Prevention Treatment of Patients with Atrial Fibrillation: Old and New</title>
            <link>http://www.medworm.com/index.php?rid=4186821&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F777u28264r036lpn%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Atrial fibrillation is the most common cause of cardioembolic ischemic stroke and has a rising prevalence worldwide. Stroke
 prevention in this condition is poised to take a substantial leap forward with the evolution of new anticoagulant medications,
 with superior properties compared to vitamin K antagonists. New, safer and more effective chronic therapy is on the horizon.
 However, many issues surrounding the management of stroke prevention after an acute stroke and during the course of chronic
 anticoagulant therapy remain to be resolved.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0161-zAuthors
		Simerpreet Bal, Departments of Clinical Neurosciences, Calgary Stroke Program, Faculty of Medicine, University of Calgary, Calgary, AB CanadaPawan Ojha, Depart...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4186821</comments>
            <pubDate>Thu, 18 Nov 2010 07:58:15 +0100</pubDate>
            <guid isPermaLink="false">4186821</guid>        </item>
        <item>
            <title>Research Advances in Amyotrophic Lateral Sclerosis, 2009 to 2010</title>
            <link>http://www.medworm.com/index.php?rid=4175468&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fvw862wq115018443%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of upper and lower motor neurons that causes progressive
 weakness and death. The breadth of research in ALS continues to grow with exciting new discoveries in disease pathogenesis
 and potential future therapeutics. There is a growing list of identified mutations in familial ALS, including those in genes
 encoding TDP-43 and FUS/TLS, which are expanding our understanding of the role of RNA modulation in ALS pathogenesis. There
 is a greater appreciation for the role of glial cells in motor neuron disease. Mitochondrial dysfunction is also being shown
 to be critical for motor neuron degeneration. In addition to pharmacotherapy, there are promising early developments with
 therapeutic implications in the...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4175468</comments>
            <pubDate>Mon, 15 Nov 2010 18:07:46 +0100</pubDate>
            <guid isPermaLink="false">4175468</guid>        </item>
        <item>
            <title>Update on Charcot-Marie-Tooth Disease</title>
            <link>http://www.medworm.com/index.php?rid=4175469&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl238l1842g337610%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Charcot-Marie-Tooth disease (CMT) disease encompasses a genetically heterogeneous group of inherited neuropathies, also known
 as hereditary motor and sensory neuropathies. CMT results from mutations in more than 40 genes expressed in Schwann cells
 and neurons causing overlapping phenotypes. The classic CMT phenotype reflects length-dependent axonal degeneration characterized
 by distal sensory loss and weakness, deep tendon reflex abnormalities, and skeletal deformities. Recent articles have provided
 insight into the molecular pathogenesis of CMT, which, for the first time, suggest potential therapeutic targets. Although
 there are currently no effective medications for CMT, multiple clinical trials are ongoing or being planned. This review will
 focus on the underly...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4175469</comments>
            <pubDate>Mon, 15 Nov 2010 18:07:45 +0100</pubDate>
            <guid isPermaLink="false">4175469</guid>        </item>
        <item>
            <title>New Information on the Genetics of Stroke</title>
            <link>http://www.medworm.com/index.php?rid=4151308&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu42m85521q274238%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Ischemic stroke, white matter hyperintensities related to small vessel ischemia, and intracranial aneurysms all show heritability.
 This review focuses on recent progress in understanding the molecular genetics of these disorders. Also reviewed is recent
 progress in understanding single-gene disorders in which stroke is a major feature of the phenotype, including CADASIL, CARASIL,
 hereditary angiopathy with nephropathy, aneurysm and muscle cramps, and Fabry disease and progress in pharmacogenomics as
 it relates to response to antiplatelet therapy.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0155-xAuthors
		James F. Meschia, Cerebrovascular Division, Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
	

	
		Journal Curre...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4151308</comments>
            <pubDate>Mon, 08 Nov 2010 07:04:32 +0100</pubDate>
            <guid isPermaLink="false">4151308</guid>        </item>
        <item>
            <title>Implications of Pharmacogenetic Testing for Patients Taking Warfarin or Clopidogrel</title>
            <link>http://www.medworm.com/index.php?rid=4133282&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh077606681h48p01%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Our knowledge of the pharmacogenetics of warfarin and clopidogrel continues to expand as we learn more about the individual
 genetic variations that contribute to the drugs’ efficacy and toxicity. We aim to review the recent developments in the field
 and discuss the clinical implications for the treatment of ischemic stroke patients. Despite recent advances, there is still
 insufficient data to suggest that routine genetic testing improves outcomes in patients treated with warfarin or clopidogrel
 for prevention of stroke.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0157-8Authors
		Megan M. Donohue, Department of Neurology, Harborview Medical Center, 325 9th Avenue, Box 359775, Seattle, WA 98104, USADavid L. Tirschwell, Department of Neurology, Harborview...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4133282</comments>
            <pubDate>Tue, 02 Nov 2010 17:34:36 +0100</pubDate>
            <guid isPermaLink="false">4133282</guid>        </item>
        <item>
            <title>Lipid Storage Myopathy</title>
            <link>http://www.medworm.com/index.php?rid=4133283&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fgw30267230765334%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Lipid storage myopathy (LSM) is pathologically characterized by prominent lipid accumulation in muscle fibers due to lipid
 dysmetabolism. Although extensive molecular studies have been performed, there are only four types of genetically diagnosable
 LSMs: primary carnitine deficiency (PCD), multiple acyl-coenzyme A dehydrogenase deficiency (MADD), neutral lipid storage
 disease with ichthyosis, and neutral lipid storage disease with myopathy. Making an accurate diagnosis, by specific laboratory
 tests including genetic analyses, is important for LSM as some of the patients are treatable: individuals with PCD show dramatic
 improvement with high-dose oral L-carnitine supplementation and increasing evidence indicates that MADD due to ETFDH mutations is riboflavin respons...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4133283</comments>
            <pubDate>Tue, 02 Nov 2010 17:34:35 +0100</pubDate>
            <guid isPermaLink="false">4133283</guid>        </item>
        <item>
            <title>Neurocritical Care of a Reperfused Brain</title>
            <link>http://www.medworm.com/index.php?rid=4133284&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc5277v1787574415%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cerebral hyperperfusion and reperfusion injuries are not infrequently encountered following in reperfusion of ischemic or
 hypoperfused brain. Mechanism of injury could be related to tissue plasminogen activator toxicity, oxidative stress, and hyperperfusion
 due to impaired cerebral autoregulation in already maximally dilated cerebral vasculature and compromised cerebral hemodynamic
 reserve. Reperfusion injury can present as headaches and seizures in mild forms and as subarachnoid hemorrhage, intracranial
 hemorrhage, cerebral edema, and encephalopathy in its most severe manifestation. Prevention and identifying those at risk
 of hyperperfusion syndromes are the best strategy. Active treatment includes basic neurocritical care with reduction of blood
 pressure to a re...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4133284</comments>
            <pubDate>Mon, 01 Nov 2010 17:59:35 +0100</pubDate>
            <guid isPermaLink="false">4133284</guid>        </item>
        <item>
            <title>Failure of Vitamin Supplementation to Lower the Risk of Recurrent Stroke</title>
            <link>http://www.medworm.com/index.php?rid=4097288&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F83426u2355681083%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s11910-010-0152-0Authors
		Harold P. Adams, Department of Neurology, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4097288</comments>
            <pubDate>Wed, 20 Oct 2010 17:33:57 +0100</pubDate>
            <guid isPermaLink="false">4097288</guid>        </item>
        <item>
            <title>Treatment of Carotid Artery Disease: Endarterectomy or Angioplasty?</title>
            <link>http://www.medworm.com/index.php?rid=4097289&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh106xl48rm275h87%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The management of carotid stenosis has enjoyed renewed interest in the neurological community in recent years due to the advent
 of endovascular approaches. In concert, progress in medical treatment of these patients has rekindled the debate regarding
 the best management of carotid stenosis overall, both for symptomatic and asymptomatic disease. For symptomatic carotid stenosis,
 the major decision required is choosing the type of intervention best suited for individual patients: carotid endarterectomy
 versus carotid artery stenting. For patients with asymptomatic carotid stenosis, intensive medical management has evolved
 significantly over the past decade to decrease the risk of ischemic stroke to match surgical intervention under most circumstances.
 This review wi...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4097289</comments>
            <pubDate>Wed, 20 Oct 2010 00:47:26 +0100</pubDate>
            <guid isPermaLink="false">4097289</guid>        </item>
        <item>
            <title>Use of MRI in the Assessment of Patients with Stroke</title>
            <link>http://www.medworm.com/index.php?rid=4073691&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fck4h771446512300%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Multimodal neuroimaging is assuming an increasingly important role in the initial evaluation and management of acute stroke
 patients in parallel with the expansion of therapeutic options. Multimodal MRI can identify the type of stroke (ischemia or
 hemorrhage), severity and location of the lesion, the patency of the intracranial vessels, the degree of cerebral perfusion,
 and the presence and size of the ischemic penumbra. This information can be used to guide both acute and long-term treatment
 decisions for stroke patients.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0150-2Authors
		Richard E. Burgess, Georgetown University Medical Center, 4000 Reservoir Road, NW, Building D, Suite 150, Washington, DC 20007, USAChelsea S. Kidwell, Georgetown University Me...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4073691</comments>
            <pubDate>Mon, 11 Oct 2010 16:55:47 +0100</pubDate>
            <guid isPermaLink="false">4073691</guid>        </item>
        <item>
            <title>Prognosis After Cardiac Arrest and Hypothermia: A New Paradigm</title>
            <link>http://www.medworm.com/index.php?rid=4044870&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl3m4972m48088860%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Before the use of hypothermia as a treatment for comatose post-cardiac arrest patients, several prognostic variables were
 widely accepted as reliable and valid for the prediction of poor outcome. Recent studies using hypothermia have reported on
 patients with recovery of consciousness in spite of absent or extensor motor responses after 3&amp;nbsp;days, absent bilateral cortical
 N20 responses after 24&amp;nbsp;h, serum neuron-specific enolase levels greater than 33&amp;nbsp;μg/L, and early myoclonus status epilepticus.
 Hypothermia and its associated use of sedative and paralytic agents may delay neurologic recovery and affect the optimal timing
 of prognostic variables. Recent developments in brain imaging may provide additional objective prognostic information and
 deserve fu...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4044870</comments>
            <pubDate>Wed, 06 Oct 2010 16:46:39 +0100</pubDate>
            <guid isPermaLink="false">4044870</guid>        </item>
        <item>
            <title>Treatment of Myasthenia Gravis</title>
            <link>http://www.medworm.com/index.php?rid=4044871&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu671pj3368134344%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Myasthenia gravis (MG) is an antibody-mediated, neuromuscular transmission disorder, which ranges in clinical manifestations
 of ocular myasthenia that may be visually disabling to myasthenic crisis with patients suffering life-threatening respiratory
 insufficiency. MG also has pathophysiologic subgroups based on presence or absence of acetylcholine receptor or muscle-specific
 kinase antibodies and presence of thymoma. Cholinesterase inhibitors partially improve weakness, but the vast majority of
 patients require therapies that moderate the autoimmune attack. Mortality of MG has been reduced over the last century, but
 adverse effects of treatment compromise patient care and rigorous evidence to guide the clinician are lacking.
 
 
	Content Type Journal ArticleDOI 10...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4044871</comments>
            <pubDate>Wed, 06 Oct 2010 16:46:38 +0100</pubDate>
            <guid isPermaLink="false">4044871</guid>        </item>
        <item>
            <title>Telemedicine or Telephone Consultation in Patients with Acute Stroke</title>
            <link>http://www.medworm.com/index.php?rid=4036357&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F15669639814nq00r%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The advantages of telephone consultations for patients with acute stroke syndromes are history of use, simplicity, availability,
 portability, short consultation time, and facile implementation. The favorable aspects of telemedicine consultations are high
 accuracy, reliability, efficacy, and effectiveness, the growing technological sophistication of the offerings and features,
 and the high grade of recommendation. Between the two modalities, telemedicine is optimal for assessing patients with acute
 stroke and superior to telephone-only evaluations. Telephone consultations can serve as an adequate ancillary, adjunctive,
 supplemental, or back-up modality for a telestroke network. With recent advances in one-way/two-way video and teleradiology
 features adapted to Smar...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4036357</comments>
            <pubDate>Mon, 04 Oct 2010 12:31:26 +0100</pubDate>
            <guid isPermaLink="false">4036357</guid>        </item>
        <item>
            <title>Neuro-ophthalmologic Complications and Manifestations of Upper and Lower Motor Neuron Facial Paresis</title>
            <link>http://www.medworm.com/index.php?rid=3968859&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj12151427n4x51j2%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The facial nerve (cranial nerve VII) courses a long pathway beginning in the precentral gyrus and ending at the facial muscles,
 lacrimal and salivary glands, and structures of the inner ear. Lesions along this pathway, clinically divided into upper and
 lower motor neuron lesions, present with unique characteristics that assist the physician in identifying the lesion site.
 The sequelae particularly of peripheral CN VII palsies, may result in significant and chronic damage to the cornea that may
 be challenging for the physician and patient.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0143-1Authors
		M. Tariq Bhatti, Departments of Ophthalmology and Medicine (Division of Neurology), Duke University Eye Center and Duke University Medical Center, 2351 Erwin R...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3968859</comments>
            <pubDate>Mon, 13 Sep 2010 05:42:32 +0100</pubDate>
            <guid isPermaLink="false">3968859</guid>        </item>
        <item>
            <title>Is the Magnesium Era for Aneurysmal Subarachnoid Hemorrhage Over?</title>
            <link>http://www.medworm.com/index.php?rid=3953824&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F354v34771026r654%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s11910-010-0134-2Authors
		Santiago Ortega-Gutierrez, Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY USAStephan A. Mayer, Division of Neurocritical Care, Department of Neurology, Columbia University College of Physicians and Surgeons, Milstein Hospital Building 8 Center, 177 Fort Washington Avenue, New York, NY 10032, USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3953824</comments>
            <pubDate>Tue, 07 Sep 2010 17:25:30 +0100</pubDate>
            <guid isPermaLink="false">3953824</guid>        </item>
        <item>
            <title>Biomarkers in Parkinson’s Disease</title>
            <link>http://www.medworm.com/index.php?rid=3932909&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk13206v14578qn34%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Biomarkers are objectively measured characteristics that are indicators of normal biological processes, pathogenic processes,
 or responses to therapeutic interventions. To date, clinical assessment remains the gold standard in the diagnosis of Parkinson’s
 disease (PD) and clinical rating scales are well established as the gold standard for tracking progression of PD. Researchers
 have identified numerous potential biomarkers that may aid in the differential diagnosis of PD and/or tracking disease progression.
 Clinical, genetic, blood and cerebrospinal fluid (proteomics, transcriptomics, metabolomics), and neuroimaging biomarkers
 may provide useful tools in the diagnosis of PD and in measuring disease progression and response to therapies. Some potential
 biomarker...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3932909</comments>
            <pubDate>Thu, 02 Sep 2010 08:25:20 +0100</pubDate>
            <guid isPermaLink="false">3932909</guid>        </item>
        <item>
            <title>The New Classification of Primary Progressive Aphasia into Semantic, Logopenic, or Nonfluent/Agrammatic Variants</title>
            <link>http://www.medworm.com/index.php?rid=3932910&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3m8644830lm81204%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Primary progressive aphasia (PPA), typically resulting from a neurodegenerative disease such as frontotemporal lobar degeneration
 or Alzheimer’s disease, is characterized by a progressive loss of specific language functions with relative sparing of other
 cognitive domains. Three variants of PPA are now recognized: semantic variant, logopenic variant, and nonfluent/agrammatic
 variant. We discuss recent work characterizing the neurolinguistic, neuropsychological, imaging and pathologic profiles associated
 with these variants. Improved reliability of diagnoses will be increasingly important as trials for etiology-specific treatments
 become available. We also discuss the implications of these syndromes for theories of language function.
 
 
	Content Type Journal Arti...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3932910</comments>
            <pubDate>Thu, 02 Sep 2010 08:25:19 +0100</pubDate>
            <guid isPermaLink="false">3932910</guid>        </item>
        <item>
            <title>Neurogenic Stuttering: Its Reticular Modulation</title>
            <link>http://www.medworm.com/index.php?rid=3913070&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F01266q09g7455822%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Emerging neurologic evidence has suggested that developmental and acquired stuttering may have a cerebral base. Investigations
 have revealed compensatory activation in the right cortical motor areas and deactivation in the left perisylvian region in
 subjects with persistent developmental stuttering. The evidence has also implicated limbic (cingulate)-basal ganglia regions.
 Increased speech fluency with treatment in such subjects eliminated compensatory brain activity and shifted activation back
 to the left hemisphere. We assess the neurology of stuttering and then present our own observations of deep brain stimulation
 of the thalamus with some ameliorating effect on the encompassing syndrome with speech dysfluency.
 
 
	Content Type Journal ArticleDOI 10.1007/s1191...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3913070</comments>
            <pubDate>Thu, 26 Aug 2010 18:19:23 +0100</pubDate>
            <guid isPermaLink="false">3913070</guid>        </item>
        <item>
            <title>Treatment Regimens for HIV Neurocognitive Dysfunctions in the Highly Active Antiretroviral Therapy (HAART) Era</title>
            <link>http://www.medworm.com/index.php?rid=3885188&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh2k4p4289878t732%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s11910-010-0141-3Authors
		Burk Jubelt, Neurology, Microbiology/Immunology, and Neuroscience, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3885188</comments>
            <pubDate>Tue, 17 Aug 2010 20:37:12 +0100</pubDate>
            <guid isPermaLink="false">3885188</guid>        </item>
        <item>
            <title>Frontotemporal Dementia and Primary Progressive Aphasia: An Update</title>
            <link>http://www.medworm.com/index.php?rid=3885189&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg5583625l5221116%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Frontotemporal dementias are syndromes of progressive dysfunction of the frontal and/or temporal lobes, either unilaterally
 or bilaterally. These syndromes were described clinically under the terms “primary progressive aphasia” in the United States
 and “frontotemporal dementia” in Europe and the United Kingdom. They are diagnosed by the clinical features of a frontal lobe
 neurobehavioral syndrome, or a language and cognitive deterioration. In recent years, molecular genetic findings in these
 syndromes, especially the tau and progranulin mutations on chromosome 17, have provided a molecular and genetic foundation
 for the understanding of frontotemporal dementia. These disorders are distinct from Alzheimer’s disease but have some overlap
 with the syndrome ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3885189</comments>
            <pubDate>Tue, 17 Aug 2010 20:25:56 +0100</pubDate>
            <guid isPermaLink="false">3885189</guid>        </item>
        <item>
            <title>Neuro-Ophthalmologic Complications of Syringobulbia</title>
            <link>http://www.medworm.com/index.php?rid=3876486&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv511811878n3jm7u%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Syringobulbia is an uncommon condition, usually a late complication of syringomyelia. It has predilection for the dorsolateral
 region of the medulla leading to damage to vestibular nuclei and their connections, as well as to the descending sympathetic
 fibers. Oscillopsia, nystagmus, and Horner syndrome are frequent manifestations of syringobulbia. Oscillopsia may be a disturbing
 symptom for the patient, whereas Horner syndrome is usually an asymptomatic finding. MRI detection of syringomyelia has led
 to earlier treatment of syringomyelia and prevention of upward extension of the cavity. This probably explains why syringobulbia
 is less frequently encountered at present. We propose to describe the neuro-ophthalmologic symptoms and signs that may be
 observed in patie...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3876486</comments>
            <pubDate>Sat, 14 Aug 2010 16:46:18 +0100</pubDate>
            <guid isPermaLink="false">3876486</guid>        </item>
        <item>
            <title>Does Rasagiline Have a Disease-Modifying Effect on Parkinson’s Disease?</title>
            <link>http://www.medworm.com/index.php?rid=3866876&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx0l7p22231247663%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s11910-010-0133-3Authors
		Shyamal H. Mehta, Movement Disorders Program, Medical College of Georgia, 1429 Harper Street, HF-1121, Augusta, GA 30912, USAJohn C. Morgan, Movement Disorders Program, Medical College of Georgia, 1429 Harper Street, HF-1121, Augusta, GA 30912, USAKapil D. Sethi, Movement Disorders Program, Medical College of Georgia, 1429 Harper Street, HF-1121, Augusta, GA 30912, USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3866876</comments>
            <pubDate>Fri, 13 Aug 2010 17:43:50 +0100</pubDate>
            <guid isPermaLink="false">3866876</guid>        </item>
        <item>
            <title>A Review of Conduction Aphasia</title>
            <link>http://www.medworm.com/index.php?rid=3866877&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm45155n5m77113x2%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In this paper, a historical overview of the interpretation of conduction aphasia is initially presented. It is emphasized
 that the name conduction aphasia was proposed by Wernicke and was interpreted as a disconnection between the temporal and
 frontal brain language areas; this interpretation was re-taken by Geschwind, attributing the arcuate fasciculus the main role
 in speech repetition disturbances and resulting in the so-called Wernicke-Geschwind model of language. With the introduction
 of contemporary neuroimaging techniques, this interpretation of conduction aphasia as a disconnection syndrome due to an impairment
 of the arcuate fasciculus has been challenged. It has been disclosed that the arcuate fasciculus does not really connect Wernicke’s
 and Broca’s...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3866877</comments>
            <pubDate>Fri, 13 Aug 2010 17:43:47 +0100</pubDate>
            <guid isPermaLink="false">3866877</guid>        </item>
        <item>
            <title>Neurologic and Muscular Complications of the 2009 Influenza A (H1N1) Pandemic</title>
            <link>http://www.medworm.com/index.php?rid=3866878&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F72q7738134762155%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In the spring of 2009 a new triple-reassortant of influenza A (H1N1) virus appeared in Mexico and rapidly spread around the
 world, becoming a pandemic that primarily infected children and uncommonly older adults. Accompanying the pandemic were associated
 neurologic and muscular syndromes that affected primarily children and included febrile seizures, encephalopathy/encephalitis
 with or without seizures, delirium, focal neurologic syndromes, Guillain-Barré syndrome, myositis, and myocarditis. Neither
 the frequency nor the severity of these syndromes appears different from those recognized during periods of infections of
 previous influenza A viruses. I review the clinical, laboratory, neuroimaging, and pathologic characteristics of the associated
 syndromes appearin...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3866878</comments>
            <pubDate>Mon, 09 Aug 2010 19:40:20 +0100</pubDate>
            <guid isPermaLink="false">3866878</guid>        </item>
        <item>
            <title>Ocular Motility of Aging and Dementia</title>
            <link>http://www.medworm.com/index.php?rid=3866879&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn5049t7k6g7j1v25%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Visual complaints in patients with dementia are varied and attributable to both visual sensory (afferent) and ocular motor
 (efferent) dysfunction. This review focuses exclusively on the efferent visual dysfunction associated with dementia and aging.
 It provides a brief overview of the most common ocular motility disturbances associated with dementia, including Alzheimer’s
 disease, Parkinson’s disease, diffuse Lewy body disease, corticobasal syndrome, progressive supranuclear palsy, frontotemporal
 lobar degeneration, Creutzfeldt-Jakob disease, and others. An introduction to the six eye movement systems and the terminology
 associated with the evaluation of each system are reviewed. Assessment of efferent visual function in patients with dementia
 may be challengi...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3866879</comments>
            <pubDate>Mon, 09 Aug 2010 19:40:18 +0100</pubDate>
            <guid isPermaLink="false">3866879</guid>        </item>
        <item>
            <title>Neurologic Consequences of the Immune Reconstitution Inflammatory Syndrome (IRIS)</title>
            <link>http://www.medworm.com/index.php?rid=3866880&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm7x240342132j134%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Although major advancements have been made in the treatment of HIV infection, graft-versus-host reactions, and autoimmune
 diseases, an unexpected consequence of treatment has been the emergence of a devastating inflammatory syndrome, termed the
 immune reconstitution inflammatory syndrome (IRIS). The pathophysiology of the syndrome is poorly understood, and the syndrome
 poses unique challenges for diagnosis and treatment. We have reviewed the neurologic manifestations of IRIS in the context
 of HIV infection as well as in the setting of treatment of autoimmune diseases such as multiple sclerosis, in which compartmental
 immune suppression may occur without an obvious underlying immune suppression. The purpose of this review is to identify common
 themes that may assis...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3866880</comments>
            <pubDate>Mon, 09 Aug 2010 19:40:17 +0100</pubDate>
            <guid isPermaLink="false">3866880</guid>        </item>
        <item>
            <title>Rare Causes of Dystonia Parkinsonism</title>
            <link>http://www.medworm.com/index.php?rid=3861792&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F672044hu33520242%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The list of genetic causes of syndromes of dystonia parkinsonism grows constantly. As a consequence, the diagnosis becomes
 more and more challenging for the clinician. Here, we summarize the important causes of dystonia parkinsonism including autosomal-dominant,
 recessive, and x-linked forms. We cover dopa-responsive dystonia, Wilson’s disease, Parkin-, PINK1-, and DJ-1-associated parkinsonism
 (PARK2, 6, and 7), x-linked dystonia-parkinsonism/Lubag (DYT3), rapid-onset dystonia-parkinsonism (DYT12) and DYT16 dystonia,
 the syndromes of Neurodegeneration with Brain Iron Accumulation (NBIA) including pantothenate kinase (PANK2)- and PLA2G6 (PARK14)-associated neurodegeneration, neuroferritinopathy, Kufor-Rakeb disease (PARK9) and the recently described SENDA
 syndrome...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3861792</comments>
            <pubDate>Sat, 07 Aug 2010 07:05:14 +0100</pubDate>
            <guid isPermaLink="false">3861792</guid>        </item>
        <item>
            <title>Quality of Life in Multiple Sclerosis: Determinants, Measurement, and Use in Clinical Practice</title>
            <link>http://www.medworm.com/index.php?rid=3776138&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx225076x1251274x%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Multiple sclerosis (MS) is a complex demyelinating disease with a relatively unpredictable course. It is well established
 that MS has a significant impact on health-related quality of life (HRQL) for individuals at all stages of the disease. It
 is argued that clinicians offer treatment to their patients for three reasons: 1) to increase longevity, 2) to prevent future
 morbidity, and 3) to make patients feel better. To assess how well they are accomplishing the third of these goals, clinicians
 have come to depend on the direct measurement of patients’ HRQL. We review the many physical and emotional symptoms and other
 consequences of MS that negatively influence HRQL, how HRQL is measured, the unique information these measures provide compared
 with clinical parame...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3776138</comments>
            <pubDate>Wed, 14 Jul 2010 23:28:59 +0100</pubDate>
            <guid isPermaLink="false">3776138</guid>        </item>
        <item>
            <title>Oral Disease-Modifying Therapies for Multiple Sclerosis: Are We There Yet?</title>
            <link>http://www.medworm.com/index.php?rid=3701612&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft510t0k1583836r4%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s11910-010-0126-2Authors
		Vijayshree Yadav, Oregon Health &amp; Science University Department of Neurology 3181 Southwest Sam Jackson Park Road, UHS-42 Portland OR 97239 USADennis Bourdette, Oregon Health &amp; Science University Department of Neurology 3181 Southwest Sam Jackson Park Road, UHS-42 Portland OR 97239 USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3701612</comments>
            <pubDate>Wed, 23 Jun 2010 20:13:15 +0100</pubDate>
            <guid isPermaLink="false">3701612</guid>        </item>
        <item>
            <title>Tarenflurbil in Patients with Mild Alzheimer’s Disease</title>
            <link>http://www.medworm.com/index.php?rid=3695346&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F527644176g647105%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s11910-010-0130-6Authors
		Karen Marder, Columbia University College of Physicians and Surgeons Sally Kerlin Professor of Neurology 630 West 168th Street New York NY 10032 USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3695346</comments>
            <pubDate>Tue, 22 Jun 2010 18:37:24 +0100</pubDate>
            <guid isPermaLink="false">3695346</guid>        </item>
        <item>
            <title>An Update on the Neurologic Applications of Botulinum Toxins</title>
            <link>http://www.medworm.com/index.php?rid=3695347&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fljm6g04237315281%2F</link>
            <description>This article highlights
 some of the common neurologic conditions currently improved by botulinum toxins and reviews the scientific evidence from research
 studies and clinical experience with these conditions.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0129-zAuthors
		Virgilio Gerald H. Evidente, Mayo Clinic Arizona Department of Neurology 13400 East Shea Boulevard Scottsdale AZ 85259 USACharles H. Adler, Mayo Clinic Arizona Department of Neurology 13400 East Shea Boulevard Scottsdale AZ 85259 USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3695347</comments>
            <pubDate>Mon, 21 Jun 2010 16:13:48 +0100</pubDate>
            <guid isPermaLink="false">3695347</guid>        </item>
        <item>
            <title>Postural Control in Multiple Sclerosis: Implications for Fall Prevention</title>
            <link>http://www.medworm.com/index.php?rid=3695348&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc1432p4162h2811r%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;People with multiple sclerosis (MS) often have poor postural control, which likely underlies their increased risk of falls.
 Based on several studies of balance and gait in MS, it appears that the primary mechanisms underlying the observed changes
 are slowed somatosensory conduction and impaired central integration. This review of the published research on balance, gait,
 and falls in people with MS demonstrates that people with MS have balance impairments characterized by increased sway in quiet
 stance, delayed responses to postural perturbations, and a reduced ability to move toward their limits of stability. These
 impairments are likely causes of falls in people with MS and are consistent with the reduced gait speed, as well as decreased
 stride length, cadence, a...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3695348</comments>
            <pubDate>Mon, 21 Jun 2010 16:13:47 +0100</pubDate>
            <guid isPermaLink="false">3695348</guid>        </item>
        <item>
            <title>What Can We Learn From Freezing of Gait in Parkinson’s Disease?</title>
            <link>http://www.medworm.com/index.php?rid=3678473&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu12j171543564350%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Freezing of gait (FOG) is defined as an episodic inability to generate effective stepping in the absence of any known cause,
 other than parkinsonism or high-level gait disorders. Substantial effort has been made to describe the clinical and kinematic
 characteristics of patients with FOG. In our review, we highlight the distinctive features of FOG in Parkinson’s disease (PD)
 and apply the knowledge of its pathophysiology in PD to other clinical situations and conditions. It is possible that FOG
 in PD represents the ultimate break in the frontal lobe–basal ganglia–cerebellar–brainstem network that controls gait. Dysrhythmic
 and discoordinated gait with abnormal scaling of stride length, as well as gait festination, likely is the primary and continuous
 abnorm...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3678473</comments>
            <pubDate>Fri, 18 Jun 2010 10:42:03 +0100</pubDate>
            <guid isPermaLink="false">3678473</guid>        </item>
        <item>
            <title>Physical Activity and Mild Cognitive Impairment and Alzheimer’s Disease</title>
            <link>http://www.medworm.com/index.php?rid=3676389&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F25j13550k1jk7r44%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Regular physical activity undoubtedly has many health benefits for all age groups. In the past decade, researchers and clinicians
 have begun to focus their attention on whether physical activity also can improve health outcomes of older adults who experience
 mild cognitive impairment (MCI) or dementia. This ongoing question is gaining relevance in light of the aging of the world
 population and with it the rise of age-related conditions, such as cognitive impairment. Not surprisingly, physical activity
 is among the potential protective lifestyle factors mentioned when strategies to delay or prevent dementia are discussed.
 The first large-scale multidomain intervention trials are under way to put this to the test. This review aims to give an overview
 of recent trial...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3676389</comments>
            <pubDate>Thu, 17 Jun 2010 09:30:39 +0100</pubDate>
            <guid isPermaLink="false">3676389</guid>        </item>
        <item>
            <title>Multiple Sclerosis and Vitamin D: A Review and Recommendations</title>
            <link>http://www.medworm.com/index.php?rid=3676388&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2559128j5823k024%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A relationship between vitamin D and several diseases, including multiple sclerosis (MS), has recently received interest in
 the scientific community. Vitamin D appears to have important actions beyond endocrine function, particularly for the immune
 system. Risk of development of MS, as well as disease severity, has been associated with vitamin D in a variety of studies.
 There remains a need for prospective studies to further establish this relationship. Given the current evidence of the potential
 benefits of vitamin D, it appears to be reasonable and safe to consider vitamin D supplementation at dosing adequate to achieve
 normal levels in patients with MS and clinically isolated syndrome.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0131-5Authors
		Andre...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3676388</comments>
            <pubDate>Thu, 17 Jun 2010 09:30:39 +0100</pubDate>
            <guid isPermaLink="false">3676388</guid>        </item>
        <item>
            <title>Emerging Oral Therapies in Multiple Sclerosis</title>
            <link>http://www.medworm.com/index.php?rid=3671461&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu0350q51x71npg65%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. The seven therapies currently approved
 by regulatory agencies are administered by subcutaneous or intramuscular injection or intravenous infusion. Many phase 2 trials
 involving oral MS therapeutics were recently completed, as were two phase 3 trials of fingolimod and one phase 3 trial of
 cladribine. Numerous other oral treatments are being investigated in ongoing phase 3 trials. Although an oral route of administration
 is attractive, these medications also present new challenges in balancing convenience, efficacy, and safety. In this review,
 we examine the safety and efficacy data from emerging oral therapies in an attempt to clarify their potential future role
 in the treatmen...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3671461</comments>
            <pubDate>Mon, 14 Jun 2010 13:52:29 +0100</pubDate>
            <guid isPermaLink="false">3671461</guid>        </item>
        <item>
            <title>Consent in Impaired Populations</title>
            <link>http://www.medworm.com/index.php?rid=3671460&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F4w3n5j7916257053%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Impairments in patients with dementia and other disorders affecting cognition may have a negative impact on their capacity
 to provide consent to treatment or to participation in research. A growing literature confirms that even patients with mild
 cognitive impairment may experience decrements in decisional abilities, findings that are more pronounced still in the early
 stages of dementia. However, most patients with mild dementia probably remain competent to provide a valid consent to treatment
 or research, and even some patients with moderate dementia may retain capacity in particular circumstances. Clinical evaluation
 of decisional competence has been augmented by structured approaches, including reliable instruments that may be used in the
 clinical setting. To ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3671460</comments>
            <pubDate>Mon, 14 Jun 2010 13:52:29 +0100</pubDate>
            <guid isPermaLink="false">3671460</guid>        </item>
        <item>
            <title>Minding the Aging Brain: Technology-Enabled Cognitive Training for Healthy Elders</title>
            <link>http://www.medworm.com/index.php?rid=3655502&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F4n703616673u1x17%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 Cognitive training refers to theory-driven behavioral intervention, ideally supported by a strong conceptual framework and specified neurocognitive
 mechanisms. Within this field, neurotechnology promises many advantages, and a growing literature establishes technology-enabled
 cognitive training as a promising modality to promote positive cognition in consumer, research, clinical, and public health
 settings. Methodologic challenges remain, and specific cognitive training recommendations for healthy elders must be tentative
 in the context of an emerging evidence base.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0124-4Authors
		Joshua R. Steinerman, Albert Einstein College of Medicine 1165 Morris Park Avenue, Room 334B Bronx NY 10461 USA
	

	
		Journal Cu...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3655502</comments>
            <pubDate>Thu, 10 Jun 2010 17:42:46 +0100</pubDate>
            <guid isPermaLink="false">3655502</guid>        </item>
        <item>
            <title>Hormonal Influences on Cognition and Risk for Alzheimer’s Disease</title>
            <link>http://www.medworm.com/index.php?rid=3655503&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F94157q863322t71p%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Research increasingly suggests that changes in estrogen levels during aging may increase the risk of Alzheimer’s disease,
 the most common type of dementia. This update reviews the newest information about estrogen and cognitive aging, including
 information regarding the role of bioavailable estrogen in older women and men, use of selective estrogen receptor modulators
 to improve cognition, and studies of genetic risk factors to elucidate the effects of endogenous estrogen on aging and cognition.
 Future trials are needed to determine whether alternate timing, dosage, formulation, or method of administration of hormone
 replacement can reduce the risk of dementia.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0122-6Authors
		Sarah C. Janicki, Columbia Univ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3655503</comments>
            <pubDate>Wed, 09 Jun 2010 20:14:19 +0100</pubDate>
            <guid isPermaLink="false">3655503</guid>        </item>
        <item>
            <title>Update on Anticonvulsant Drugs</title>
            <link>http://www.medworm.com/index.php?rid=3588775&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F00734w5538q235n4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In 2009, the US Food and Drug Administration approved three medications for the treatment of epilepsy: rufinamide, lacosamide,
 and vigabatrin. In addition, extended-release formulations of lamotrigine and levetiracetam were approved recently. When added
 to the dozen medications for treating epilepsy, the choice is a luxury in terms of additional options, but also a challenge
 for practitioners to use them all with expertise. Recently, there has been much interest surrounding medications for epilepsy
 and their possible association with osteoporosis, safety during pregnancy, biological equivalence to generic versions, and
 possible association with higher rates of suicidality. This review discusses these issues and provides a current overview
 for the medical managemen...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3588775</comments>
            <pubDate>Thu, 20 May 2010 14:03:07 +0100</pubDate>
            <guid isPermaLink="false">3588775</guid>        </item>
        <item>
            <title>Suicidality in Epilepsy and Possible Effects of Antiepileptic Drugs</title>
            <link>http://www.medworm.com/index.php?rid=3577165&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn167h88h27u1v571%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Suicide is an important cause of premature death, and people with epilepsy are thought to be at increased risk for suicide.
 Antiepileptic drugs (AEDs) continue to be the mainstay of epilepsy treatment, but the benefits of seizure control must be
 balanced with their psychotropic potential. In recent years, suicidality has been recognized as a complication of several
 groups of drugs and, most recently, AEDs were implicated in an alert by the US Food and Drug Administration. The risk of suicidal
 ideation and behavior as side effects of AED treatment is low, and in people with epilepsy, such a risk must be balanced against
 the risk of not treating the seizures.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0117-3Authors
		Marco Mula, University Hospital Maggi...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3577165</comments>
            <pubDate>Mon, 17 May 2010 05:59:26 +0100</pubDate>
            <guid isPermaLink="false">3577165</guid>        </item>
        <item>
            <title>Limb–Girdle and Congenital Muscular Dystrophies: Current Diagnostics, Management, and Emerging Technologies</title>
            <link>http://www.medworm.com/index.php?rid=3567858&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F06w6240k228g2852%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The muscular dystrophies show muscle degeneration and regeneration (necrotizing myopathy) on muscle biopsy, typically associated
 with elevated serum creatine kinase, and muscle weakness. In 1986, the first causative gene was identified for the most prevalent
 and best-characterized form of muscular dystrophy, Duchenne muscular dystrophy. Over the past 25&amp;nbsp;years, the number of other
 genes determined to cause different subtypes has grown rapidly. This review gives a synopsis of the 45 genetically defined
 types of muscular dystrophies and describes the clinical, pathologic, and molecular aspects of each disease. DNA diagnosis
 remains the most sensitive and specific method for differential diagnosis, but molecular diagnostics can be expensive and
 complex (because o...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3567858</comments>
            <pubDate>Fri, 14 May 2010 09:36:36 +0100</pubDate>
            <guid isPermaLink="false">3567858</guid>        </item>
        <item>
            <title>Primary Brain Tumors in the Elderly</title>
            <link>http://www.medworm.com/index.php?rid=3563767&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F202w12740g718884%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The incidence of primary brain tumors is highest in elderly patients, and advanced age often is a negative prognostic factor.
 Nevertheless, large randomized studies in this population are scarce. Elderly patients with primary brain tumors also present
 unique challenges, such as the presence of multiple comorbidities and polypharmacy, decreased tolerance to chemotherapy, and
 an increased risk for radiation-induced neurotoxicity. This review gives an overview of the treatment options for older patients
 with glioblastoma and other gliomas, primary central nervous system lymphomas (PCNSLs), and meningiomas. Selected elderly
 glioblastoma patients with good performance status may benefit from aggressive treatment with surgical resection, radiotherapy,
 and possibly chemo...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3563767</comments>
            <pubDate>Wed, 12 May 2010 07:04:12 +0100</pubDate>
            <guid isPermaLink="false">3563767</guid>        </item>
        <item>
            <title>What Is Intractable Epilepsy, and When (If Ever) Does It Remit with Medical Treatment?</title>
            <link>http://www.medworm.com/index.php?rid=3555934&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm51940j20759120t%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s11910-010-0115-5Authors
		Carl W. Bazil, Columbia University College of Physicians and Surgeons 710 West 168th Street New York NY 10032 USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3555934</comments>
            <pubDate>Sat, 08 May 2010 10:03:29 +0100</pubDate>
            <guid isPermaLink="false">3555934</guid>        </item>
        <item>
            <title>Recent Advances in the Genetics of Mitochondrial Encephalopathies</title>
            <link>http://www.medworm.com/index.php?rid=3545355&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft7m6414l28381m05%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Mitochondrial encephalopathy, the most common neurometabolic disorder, may be caused by mutations in approximately 100 different
 genes and may present with various symptoms, such as seizures, ataxia, myopathy, cognitive impairment, blindness, and stroke.
 Fewer than 50% of patients with mitochondrial encephalopathy receive a molecular diagnosis, primarily because of the large
 degree of clinical and genetic heterogeneity among patients and the limited knowledge of the genes involved in mitochondrial
 function. Here we review the most recent discoveries of genes associated with mitochondrial disease with variable neuropathology.
 All these genes have been identified via homozygosity mapping or linkage analysis; however, advances in sequencing technology
 indicate that t...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3545355</comments>
            <pubDate>Thu, 06 May 2010 08:03:47 +0100</pubDate>
            <guid isPermaLink="false">3545355</guid>        </item>
        <item>
            <title>Sudden Unexpected Death in Epilepsy</title>
            <link>http://www.medworm.com/index.php?rid=3545356&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2036737804058p15%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Sudden unexpected death in epilepsy (SUDEP) is a significant cause of death for people with epilepsy. Recent research suggests
 that multiple factors may contribute and that both cardiac and respiratory mechanisms are involved. Both human and animal
 data suggest that specific genetic factors might play a role in some cases. Recent animal data suggest that serotonin might
 affect respiratory mechanisms and may be involved. Both cardiac and respiratory abnormalities are more likely with generalized
 tonic–clonic seizures. Uncontrolled epilepsy, particularly with generalized tonic–clonic seizures, appears to be the most
 highly associated modifiable risk factor for SUDEP.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0116-4Authors
		Maromi Nei, Jefferson Med...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3545356</comments>
            <pubDate>Thu, 06 May 2010 08:03:46 +0100</pubDate>
            <guid isPermaLink="false">3545356</guid>        </item>
        <item>
            <title>An Update on Tourette Syndrome</title>
            <link>http://www.medworm.com/index.php?rid=3545357&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh5726r2350421644%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Recent advances in our understanding of the phenomenology, etiology, pathophysiology, and treatment of Tourette syndrome are
 discussed. Tourette syndrome appears to involve dysfunction of limbic and somatosensory “traffic” through the basal ganglia,
 within corticostriatal-thalamocortical circuits. Dynamic alterations in the balance of these inputs may dictate the manifestations
 (sensory, motor, affective, and behavioral) of the disorder at any given time. Individualized assessment and treatment are
 the keys to optimal treatment of this condition.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0118-2Authors
		Thomas E. Kimber, Royal Adelaide Hospital Neurology Unit North Terrace Adelaide SA 5000 Australia
	

	
		Journal Current Neurology and Neuroscience...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3545357</comments>
            <pubDate>Thu, 06 May 2010 08:03:45 +0100</pubDate>
            <guid isPermaLink="false">3545357</guid>        </item>
        <item>
            <title>Selecting Patients for Epilepsy Surgery</title>
            <link>http://www.medworm.com/index.php?rid=3533683&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F76t2q06327m8k304%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;About one third of patients with focal epilepsy experience seizures despite adequate medical treatment. In this population,
 successful epilepsy surgery improves life expectancy and health-related quality of life, while reducing health care costs
 as a result of reduced hospital admissions, emergency department visits, and use of antiepileptic drugs. The effectiveness
 of epilepsy surgery and low incidence of surgical complications have been established by numerous studies over several decades.
 The International League Against Epilepsy recently issued a definition of drug-resistant epilepsy for early identification
 of patients who are unlikely to be treated successfully with medical therapy alone. Potential surgical candidates are identified
 through a detailed seizur...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3533683</comments>
            <pubDate>Sat, 01 May 2010 07:14:03 +0100</pubDate>
            <guid isPermaLink="false">3533683</guid>        </item>
        <item>
            <title>Parkinson’s Disease Dementia</title>
            <link>http://www.medworm.com/index.php?rid=3524021&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8521660713775334%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Dementia associated with Parkinson’s disease (PDD) is a common problem and one that is associated with significant morbidity
 and mortality. Over the past decade, increasing research efforts and funding have been directed toward an improved understanding
 of PDD. Despite these efforts, fundamental gaps remain in our knowledge. Consequently, therapeutic progress has been frustratingly
 slow and incomplete. To significantly affect PDD, novel “disease-modifying” agents, rather than more traditional neurotransmitter
 replacement approaches, likely will be required.
 
 
	Content Type Journal ArticleDOI 10.1007/s11910-010-0113-7Authors
		Mary J. Docherty, Newcastle University Institute for Ageing and Health Newcastle upon Tyne UKDavid J. Burn, Newcastle University Insti...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3524021</comments>
            <pubDate>Thu, 29 Apr 2010 21:16:35 +0100</pubDate>
            <guid isPermaLink="false">3524021</guid>        </item>
        <item>
            <title>Immunotherapy Approaches for Malignant Glioma From 2007 to 2009</title>
            <link>http://www.medworm.com/index.php?rid=3502745&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F13l761315722l533%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Malignant glioma is a deadly disease for which there have been few therapeutic advances over the past century. Although previous
 treatments were largely unsuccessful, glioma may be an ideal target for immune-based therapy. Recently, translational research
 led to several clinical trials based on tumor immunotherapy to treat patients with malignant glioma. Here we review 17 recent
 glioma immunotherapy clinical trials, published over the past 3&amp;nbsp;years. Various approaches were used, including passive transfer
 of naked and radiolabeled antibodies, tumor antigen-specific peptide immunization, and the use of patient tumor cells with
 or without dendritic cells as vaccines. We compare and discuss the current state of the art of clinical immunotherapy treatment,
 as well...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3502745</comments>
            <pubDate>Fri, 23 Apr 2010 08:32:57 +0100</pubDate>
            <guid isPermaLink="false">3502745</guid>        </item>
        <item>
            <title>The Role of Glucocerebrosidase Mutations in Parkinson Disease and Lewy Body Disorders</title>
            <link>http://www.medworm.com/index.php?rid=3482780&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F015r6440672h8m06%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Mutations in the gene encoding glucocerebrosidase (GBA), the enzyme deficient in the lysosomal storage disorder Gaucher disease, are associated with the development of Parkinson
 disease and other Lewy body disorders. In fact, GBA variants are currently the most common genetic risk factor associated with parkinsonism, and identified subjects with Parkinson
 disease are more than five times more likely to carry mutations in GBA. The mechanisms underlying this association are not known, but proposed theories include enhanced protein aggregation, alterations
 in lipid levels, and autophagy-lysosomal dysfunction promoting the retention of undegraded proteins. We review the genetic
 studies linking GBA to parkinsonism, as well as several of the mechanisms postulated to expla...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3482780</comments>
            <pubDate>Wed, 14 Apr 2010 16:54:09 +0100</pubDate>
            <guid isPermaLink="false">3482780</guid>        </item>
        <item>
            <title>Hypocretin Ligand Deficiency in Narcolepsy: Recent Basic and Clinical Insights</title>
            <link>http://www.medworm.com/index.php?rid=3432650&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq40000h43x6w712x%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations,
 and sleep paralysis. Both sporadic and familial forms exist in humans. Recently, the major pathophysiology of human narcolepsy
 was indicated, based on discovery, through animal study, of narcolepsy genes involved in the pathology of hypocretin/orexin
 ligand and its receptor. Hypocretin ligand deficiency is found in most patients with narcolepsy with cataplexy. This deficiency
 likely is the result of postnatal cell death of hypocretin neurons, and involvement of autoimmune mechanisms is suggested.
 Hypocretin deficiency also is found in symptomatic narcolepsy and excessive daytime sleepiness with neurologic conditions,
 including immune-mediated...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3432650</comments>
            <pubDate>Wed, 31 Mar 2010 05:56:46 +0100</pubDate>
            <guid isPermaLink="false">3432650</guid>        </item>
        <item>
            <title>Hypocretins in the Control of Sleep and Wakefulness</title>
            <link>http://www.medworm.com/index.php?rid=3424695&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq205h12333213280%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;During the past 10&amp;nbsp;years since the discovery of hypocretins (Hcrt, also called orexins), the list of their physiologic implications
 has been growing, from their primary roles in the sleep–wake cycle and feeding to the control of the cardiovascular system,
 pain, locomotion, stress, and addiction as well as their involvement in psychiatric disorders such as panic, anxiety, and
 depression. This diverse set of functions is consistent with the localization of Hcrt neurons in the lateral hypothalamus,
 a major integrating center of sensory inputs and emotional processes, and their widespread excitatory projections throughout
 the brain. Newly developed optical tools allow us to manipulate the activity of genetically identified neurons with millisecond
 precision in ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3424695</comments>
            <pubDate>Mon, 29 Mar 2010 17:15:16 +0100</pubDate>
            <guid isPermaLink="false">3424695</guid>        </item>
        <item>
            <title>Neurocognitive Function in Brain Tumors</title>
            <link>http://www.medworm.com/index.php?rid=3403720&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F4q41250261v30vu8%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cognitive dysfunction associated with both the disease and the adverse effects of radiotherapy (RT) and chemotherapy is a
 significant problem among brain tumor patients. Currently, it is considered the most frequent complication among long-term
 survivors. A review of the literature indicates that whole-brain RT alone or in combination with chemotherapy results in cognitive
 dysfunction more pronounced than from either partial RT or chemotherapy alone. The cognitive domains sensitive to treatment
 adverse effects include attention, executive functions, memory, and graphomotor speed. An increasing number of studies and
 clinical trials have incorporated cognitive outcome measures and have provided relevant information about therapy-related
 neurotoxicity and the inciden...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3403720</comments>
            <pubDate>Tue, 23 Mar 2010 18:08:28 +0100</pubDate>
            <guid isPermaLink="false">3403720</guid>        </item>
        <item>
            <title>Genetics of Primary Torsion Dystonia</title>
            <link>http://www.medworm.com/index.php?rid=3403722&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb3628667342m8v80%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Advances in the genetics of dystonia have further elucidated the pathophysiology of this clinically and etiologically heterogeneous
 group of movement disorders. Currently, 20 monogenic forms of dystonia, designated by the acronym DYT, are grouped as 1) pure dystonias, 2) dystonia-plus syndromes, and 3) paroxysmal dystonias/dyskinesias. We summarize recently
 discovered genes and loci, including the 1) detection of two primary dystonia genes (DYT6, DYT16), 2) identification of the
 DYT17 locus, 3) association of a dystonia/dyskinesia phenotype with a gene previously linked to GLUT1 (glucose transporter
 of the blood–brain barrier) deficiency syndrome (DYT18), 4) designation of paroxysmal kinesigenic and nonkinesigenic dyskinesia
 as DYT19 and DYT20, and 5) redefinitio...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3403722</comments>
            <pubDate>Tue, 23 Mar 2010 18:08:27 +0100</pubDate>
            <guid isPermaLink="false">3403722</guid>        </item>
        <item>
            <title>Ependymomas in Adults</title>
            <link>http://www.medworm.com/index.php?rid=3403721&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk14403811777980r%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Ependymomas are rare primary central nervous system tumors in adults. They occur most commonly in the spinal cord, where histopathologic
 evaluation is critical to differentiate the grade I myxopapillary ependymoma from the grade II ependymoma or grade III anaplastic
 ependymoma. Brain ependymomas are either grade II or III. Treatment for all grades and types includes maximum surgical resection.
 For myxopapillary ependymoma, complete removal while maintaining capsule integrity may be curative. Some grade II ependymomas
 may be observed carefully after imaging confirms complete resection, but grade III tumors require adjuvant radiation treatment.
 Radiation commonly is given to the region of tumor, except in cases in which there is imaging or cerebrospinal fluid evidenc...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3403721</comments>
            <pubDate>Tue, 23 Mar 2010 18:08:27 +0100</pubDate>
            <guid isPermaLink="false">3403721</guid>        </item>
        <item>
            <title>The Role of Temozolomide in Elderly Patients with Glioblastoma</title>
            <link>http://www.medworm.com/index.php?rid=3394924&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj07q61258447724w%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s11910-010-0106-6Authors
		Lauren E. Abrey, Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10065 USA
	

	
		Journal Current Neurology and Neuroscience ReportsOnline ISSN 1534-6293Print ISSN 1528-4042 (Source: Current Neurology and Neuroscience Reports)</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3394924</comments>
            <pubDate>Sat, 20 Mar 2010 11:11:27 +0100</pubDate>
            <guid isPermaLink="false">3394924</guid>        </item>
        <item>
            <title>Cortical Spreading Depression and Migraine</title>
            <link>http://www.medworm.com/index.php?rid=3386825&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fhv25wm44634035g6%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cortical spreading depression, a slowly propagating wave of transient neuronal and glial depolarization, is widely accepted
 as the electrophysiologic substrate of migraine aura and a trigger for headache. Recent clinical and experimental evidence
 reinforces the putative role of cortical spreading depression in migraine pathophysiology. Imaging studies in migraineurs
 demonstrated hemodynamic changes consistent with cortical spreading depression during aura, whereas recent animal studies
 helped unravel pathophysiologic aspects such as the triggering mechanisms, genetic and hormonal modulation, and potential
 therapeutic targets. Here, we provide an overview of recent advances in our understanding of migraine pathophysiology and
 treatment.
 
 
	Content Type Journal Ar...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386825</comments>
            <pubDate>Thu, 18 Mar 2010 15:40:13 +0100</pubDate>
            <guid isPermaLink="false">3386825</guid>        </item>
        <item>
            <title>Management of Low-Grade Glioma</title>
            <link>http://www.medworm.com/index.php?rid=3382555&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7684v435q5213j48%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The optimal management of patients with low-grade glioma (LGG) is controversial. The controversy largely stems from the lack
 of well-designed clinical trials with adequate follow-up to account for the relatively long progression-free survival and
 overall survival of patients with LGG. Nonetheless, the literature increasingly suggests that expectant management is no longer
 optimal. Rather, there is mounting evidence supporting active management including consideration of surgical resection, radiotherapy,
 chemotherapy, molecular and histopathologic characterization, and use of modern imaging techniques for monitoring and prognostication.
 In particular, there is growing evidence favoring extensive surgical resection and increasing interest in the role of chemotherapy
...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3382555</comments>
            <pubDate>Wed, 17 Mar 2010 15:51:58 +0100</pubDate>
            <guid isPermaLink="false">3382555</guid>        </item>
        <item>
            <title>Synapse Pathology in Psychiatric and Neurologic Disease</title>
            <link>http://www.medworm.com/index.php?rid=3382556&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx6p453640765r50h%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Inhibitory and excitatory synapses play a fundamental role in information processing in the brain. Excitatory synapses usually
 are situated on dendritic spines, small membrane protrusions that harbor glutamate receptors and postsynaptic density components
 and help transmit electrical signals. In recent years, it has become evident that spine morphology is intimately linked to
 synapse function—smaller spines have smaller synapses and support reduced synaptic transmission. The relationship between
 synaptic signaling, spine shape, and brain function is never more apparent than when the brain becomes dysfunctional. Many
 psychiatric and neurologic disorders, ranging from mental retardation and autism to Alzheimer’s disease and addiction, are
 accompanied by alterati...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3382556</comments>
            <pubDate>Wed, 17 Mar 2010 15:51:57 +0100</pubDate>
            <guid isPermaLink="false">3382556</guid>        </item>
        <item>
            <title>Rehabilitation After Stroke: Current State of the Science</title>
            <link>http://www.medworm.com/index.php?rid=3363602&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F166l050374401174%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Stroke rehabilitation is evolving into a clinical field based on the neuroscience of recovery and restoration. There has been
 substantial growth in the number and quality of clinical trials performed. Much effort now is directed toward motor restoration
 and is being led by trials of constraint-induced movement therapy. Although the results do not necessarily support that constraint-induced
 movement therapy is superior to other training methods, this treatment has become an important vehicle for developing clinical
 trial methods and studying the physiology underlying activity-based rehabilitation strategies. Other promising interventions
 include robotic therapy delivery, magnetic and electrical cortical stimulation, visualization, and constraint-driven aphasia
 ther...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3363602</comments>
            <pubDate>Fri, 12 Mar 2010 06:51:34 +0100</pubDate>
            <guid isPermaLink="false">3363602</guid>        </item>
        <item>
            <title>The Genetics of Pediatric Brain Tumors</title>
            <link>http://www.medworm.com/index.php?rid=3362298&amp;cid=s_35940_168_f&amp;fid=35940&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0261r86246100018%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Brain tumors are the most common childhood solid malignancy and the leading cause of cancer-related death in children. Medulloblastoma,
 ependymoma, supratentorial primitive neuroectodermal tumors, and pilocytic astrocytoma are the most prevalent types, all of
 which are clinically, histologically, and genetically heterogeneous. Despite an incomplete molecular understanding of these
 tumors, we have made significant headway in the past 5&amp;nbsp;years in identifying and classifying important genetic alterations
 and pathways central to the disease process. This review summarizes our current state of knowledge, emphasizes recent seminal
 findings in the field, and proposes future research efforts needed to further characterize the genetic basis of pediatric
 brain tumors.
 ...</description>
            <author>Current Neurology and Neuroscience Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3362298</comments>
            <pubDate>Thu, 11 Mar 2010 18:26:48 +0100</pubDate>
            <guid isPermaLink="false">3362298</guid>        </item>
    </channel>
</rss>

